Annual report 2013
Transcription
Annual report 2013
RAPPORT ANNUEL 2013 Les annexes Sommaire LES ÉQUIPES DE RECHERCHE DE GUSTAVE ROUSSY _ 4 PUBLICATIONS INTERNATIONALES DE GUSTAVE ROUSSY _ 7 LES ÉQUIPES DE RECHERCHE DE GUSTAVE ROUSSY Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse Responsable : Pr Fabrice André Unité : UMR 981 Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse Plasticité du génome et cellule B Responsable : Dr Saïd Aoufouchi Unité : UMR 8200 Stabilité génétique et oncogenèse Rôle de la traduction d’ARNm dans la présentation antigénique Responsable : Dr Sébastien Apcher Unité : UMR 1015 Régulation des fonctions effectrices anti-tumorales par les cellules dendritiques et les exosomes : vers la désignation Génétique des tumeurs Responsable : Dr Olivier Bernard Unité : UMR 985 Génétique des tumeurs Signalisation, Rho GTPases et progression tumorale Responsable : Dr Jacques Bertoglio Unité : UMR 749 Signalisation, Rho GTPases et progression tumorale Diversité phénotypique des tumeurs solides : rôles du microenvironnement tumoral et des micro-ARN Responsable : Dr Pierre Busson Unité : UMR 8126 Signalisation, noyaux et innovations en cancérologie Nutrition, Hormones et santé de la femme Responsable : Dr Françoise Clavel-Chapelon Unité : UMR 1018 Centre de recherche en épidémiologie et santé des populations Hôpital Paul Brousse Résistance tumorale à la lyse et influence du micro-environnement Responsable : Dr Salem Chouaib Unité : UMR 753 Immunologie des tumeurs humaines - Interaction effecteurs cytotoxiques - Système tumoral Radiosensibilité Tumorale et mort cellulaire Responsables : Pr Eric Deutsch / Dr. Jean-Luc Perfettini Unité : UMR 1030 Radiosensibilité des tumeurs et tissus sains Espèces réactives de l’oxygène et radiocarcinogenèse Responsable : Dr Corinne Dupuy Unité : UMR 8200 Stabilité génétique et oncogenèse 04 annexes rapport annuel / Gustave Roussy 2013 Rétrovirus endogènes et éléments rétroïdes des eucaryotes supérieurs Responsable : Dr Thierry Heidmann Unité : UMR 8122 Rétrovirus endogènes et éléments rétroïdes des eucaryotes supérieurs Invasion collective et morphogénèse épithéliale Responsable : Dr Fanny Jaulin Unité : UMR 8200 Stabilité génétique et oncogenèse Polymérases translésionnelles et cancer Responsable : Dr Patricia Kannouche Unité : UMR 8200 Stabilité génétique et oncogenèse Oncogenèse et progression tumorale du mélanome Responsable : Dr Mehdi Khaled Unité : UMR 753 Immunologie des tumeurs humaines - Interaction effecteurs cytotoxiques - Système tumoral Apoptose, cancers et immunité Responsable : Pr Guido Kroemer Unité : UMR 848 Apoptose, cancers et immunité Imagerie multimodale en cancérologie Responsable : Dr Nathalie Lassau Unité : UMR 8081 - IR4M Imagerie par résonance magnétique médicale et multimodalités - UPS Orsay Maintenance des génomes, microscopies moléculaires et bionanosciences Responsable : Dr Éric Le Cam Unité : UMR 8126 Signalisation, noyaux et innovations en cancérologie Processus nucléaires et signalisation apoptotique - Innovations technologiques à visées exploratoires et thérapeutiques Responsable : Dr Marc Lipinski Unité : UMR 8126 Signalisation, noyaux et innovations en cancérologie Recombinaison / Réparation et cancer (REC) Responsable : Bernard Lopez Unité : UMR 8200 Stabilité génétique et oncogenèse Microenvironnement et auto-renouvellement des cellules souches normales et leucémiques Responsable : Dr Fawzia Louache Unité : UMR 1009 Hématopoïèse normale et pathologique Antigènes tumoraux et réactivité lymphocytaire T dans le carcinome bronchique Responsable : Dr Fathia Mami-Chouaib Unité : UMR 753 Immunologie des tumeurs humaines - Interaction effecteurs cytotoxiques - Système tumoral Gustave Roussy 2013 / annexes rapport annuel 05 Parcours de soins coordonné et personnalisé, Coordination pour la Mesure de la Performance et l’Amélioration de la Qualité Hospitalière Responsable : Pr Etienne Minvielle Unité : UMR 750 - Equipe d’Accueil Management des Organisations de Santé (EHESP) – CNRS Villejuif Vectorologie et thérapeutiques anti-cancéreuses Responsable : Dr Lluis Mir Unité : UMR 8203 Vectorologie et thérapeutiques anti-cancéreuses Génétique et biologie des cancers du rein Responsable : Pr Stéphane Richard Unité : UMR 753 Immunologie des tumeurs humaines - Interaction effecteurs cytotoxiques - Système tumoral Maladies de la réparation de l’ADN Responsable : Dr Filippo Rosselli Unité : UMR 8200 Stabilité génétique et oncogenèse Etude des protéines impliquées dans la réparation de l’ADN endommagé par les radicaux libres générés par le métabolisme cellulaire, les médicaments ou l’environnement Responsable : Dr Murat Saparbaev Unité : UMR 8200 Stabilité génétique et oncogenèse Hémopathies myéloïdes et lymphoïdes - Physiopathologie et recherche translationnelle Responsable : Pr Eric Solary Unité : UMR 1009 Hématopoïèse normale et pathologique Erythropoïèse et mégacaryocytopoïèse normales et pathologiques Responsable : Dr William Vainchenker Unité : UMR 1009 Hématopoïèse normale et pathologique Epidémiologie des cancers : radiocarcinogenèse et effet iatrogène des traitements anticancéreux Responsable : Dr Florent de Vathaire Unité : UMR 1018 Centre de recherche en épidémiologie et santé des populations Hôpital Paul Brousse Immunologie des tumeurs et Immunothérapie Responsable : Pr Laurence Zitvogel Unité : UMR 1015 Régulation des fonctions effectrices anti-tumorales par les cellules dendritiques et les exosomes : vers la désignation 06 annexes rapport annuel / Gustave Roussy 2013 PUBLICATIONS INTERNATIONALES DE GUSTAVE ROUSSY A impact factor compris entre 5 et 10 (254 publications) [1]Pernemalm M., De Petris L., Branca R.M., Forshed J., Kanter L., Soria J.C., Girard P., Validire P., Pawitan Y., Van Den Oord J., Lazar V., Paishlman S., Lewensohn R., and Lehtiö J. Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism. [2013] Journal of Proteome Research (12) 9 : 3934-3943. Impact factor : 5.001 [2]Michels J., Vitale I., Senovilla L., Enot D.P., Garcia P., Lissa D., Olaussen K.A., Brenner C., Soria J.C., Castedo M., and Kroemer G. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. [2013] Cell Cycle (12) 6 : 877-883. Impact factor : 5.006 [3]Bauer M.A., Carmona-Guttiérrez D., Ruckenstuhl C., Reisenbichler A., Megalou E.V., Eisenberg T., Magnes C., Jungwirth H., Sinner F.M., Pieber T.R., Fröhlich K.U., Kroemer G., Tavernarakis N., and Madeo F. Spermidine promotes mating and fertilization efficiency in model organisms. [2013] Cell Cycle (12) 2 : 346-352. Impact factor : 5.006 [4]Boilève A., Senovilla L., Vitale I., Lissa D., Martins I., Métivier D., Van Den Brink S., Clevers H., Galluzzi L., Castedo M., and Kroemer G. Immunosurveillance against tetraploidization-induced colon tumorigenesis. [2013] Cell Cycle (12) 3 : 473-479. Impact factor : 5.006 [5]Bonora M., Bononi A., De Marchi E., Giorgi C., Lebiedzinska M., Marchi S., Patergnani S., Rimessi A., Suski J.M., Wojtala A., Wieckowski M.R., Kroemer G., Galluzzi L., and Pinton P. Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition. [2013] Cell Cycle (12) 4 : 674-683. Impact factor : 5.006 [6]Galluzzi L., Goubar A., Olaussen K.A., Vitale I., Senovilla L., Michels J., Robin A., Dorvault N., Besse B., Validire P., Fouret P., Behrens C., Wistuba I.I., Soria J.C., and Kroemer G. Prognostic value of LIPC in non-small cell lung carcinoma. [2013] Cell Cycle (12) 4 : 647-654. Impact factor : 5.006 [7]Galluzzi L., Marsili S., Vitale I., Senovilla L., Michels J., Garcia P., Vacchelli E., Chatelut E., Castedo M., and Kroemer G. Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. [2013] Cell Cycle (12) 3 : 417-421. Impact factor : 5.006 [8]Jemaa M., Galluzzi L., Kepp O., Castedo M., Rello-Varona S., Vitale I., and Kroemer G. Transgenerational cell fate profiling: A method for the graphical presentation of complex cell cycle alterations. [2013] Cell Cycle (12) 1 : 183-190. Impact factor : 5.006 [9]Lainey E., Wolfromm A., Sukkurwala A.Q., Micol J.B., Fenaux P., Galluzzi L., Kepp O., and Kroemer G. EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells. [2013] Cell Cycle (12) 18 : 2978-2991. Impact factor : 5.006 [10] Spaggiari S., Kepp O., Rello-Varona S., Chaba K., Adjemian S., Pype J., Galluzzi L., Lemaire M., and Kroemer G. Antiapoptotic activity of argon and xenon. [2013] Cell Cycle (12) 16 : 2636-2642. Impact factor : 5.006 [11] Tuloup-Minguez V., Hamaï A., Greffard A., Nicolas V., Codogno P., and Botti J. Autophagy modulates cell migration and ß1 integrin membrane recycling. [2013] Cell Cycle (12) 20 : 3317-3328. Impact factor : 5.006 [12] Friboulet L., Postel-Vinay S., Sourisseau T., Adam J., Stoclin A., Ponsonnailles F., Dorvault N., Commo F., Saulnier P., Salome-Desmoulez S., Pottier G., André F., Kroemer G., Soria J.C., and Olaussen K.A. ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. [2013] Cell Cycle (12) 20 : 3298-3306. Impact factor : 5.006 [13] Jakszyn P., Lujan-Barroso L., Agudo A., Bueno-de-Mesquita H.B., Molina E., Sanchez M.A.J., Fonseca-Nunes A., Siersema P.D., Matiello A., Tumino R., Saieva C., Pala V., Vineis P., Boutron-Ruault M.C., Racine A., Bastide N., Travis R.C., Khaw K.T., Riboli E., Murphy N., Vergnaud A.C., Trichopoulou A., Valanou E., Oikonomidou E., Weiderpass E., Skeie G., Johansen D., Lindkvist B., Johansson M., Duarte-Salles T., Freisling H., Barricarte A., Ma Huerta J., Amiano P., Tjonneland A., Overvad K., Kuehn T., Grote V., Boeing H., Peeters P.H.M., and Gonzalez C.A. Meat and heme iron intake and esophageal adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition study. [2013] International Journal of Cancer (133) 11 : 2744-2750. Impact factor : 5.007 [14] Allen N.E., Appleby P.N., Key T.J., Bueno-de-Mesquita H.B., Ros M.M., Kiemeney L.A.L.M., Tjonneland A., Roswall N., Overvad K., Weikert S., Boeing H., Chang-Claude J., Teucher B., Panico S., Sacerdote C., Tumino R., Palli D., Sieri S., Peeters P., Quiros J.R., Jakszyn P., Molina-Montes E., Chirlaque M.D., Ardanaz E., Dorronsoro M., Khaw K.T., Wareham N., Ljungberg B., Hallmans G., Ehrnström R., Ericson U., Gram I.T., Parr C.L., Trichopoulou A., Karapetyan T., Dilis V., Clavel-Chapelon F., Boutron-Ruault M.C., Fagherrazzi G., Romieu I., Gunter M.J., and Riboli E. Macronutrient intake and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition. [2013] International Journal of Cancer (132) 3 : 635-644. Impact factor : 5.007 Gustave Roussy 2013 / annexes rapport annuel 07 [15] Buckland G., Travier N., Cottet V., Gonzalez C.A., Lujan-Barroso L., Agudo A., Trichopoulou A., Lagiou P., Trichopoulos D., Peeters P.H., May A., Bueno-de-Mesquita H.B., Bvan Duijnhoven F.J., Key T.J., Allen N., Khaw K.T., Wareham N., Romieu I., Mccormack V., Boutron-Ruault M., Clavel-Chapelon F., Panico S., Agnoli C., Palli D., Tumino R., Vineis P., Amiano P., Barricarte A., Rodriguez L., Sanchez M.J., Chirlaque M.D., Kaaks R., Teucher B., Boeing H., Bergmann M.M., Overvad K., Dahm C.C., Tjonneland A., Olsen A., Manjer J., Wirfält E., Hallmans G., Johansson I., Lund E., Hjartaker A., Skeie G., Vergnaud A.C., Norat T., Romaguera D., and Riboli E. Adherence to the mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study. [2013] International Journal of Cancer. Impact factor : 5.007 [16] Duell E.J., Travier N., Lujan-Barroso L., Dossus L., Boutron-Ruault M.C., Clavel-Chapelon F., Tumino R., Masala G., Krogh V., Panico S., Ricceri F., Luisa Redondo M., Dorronsoro M., Molina-Montes E., Huerta J.M., Barricarte A., Khaw K.T., Wareham N.J., Allen N.E., Travis R., Siersema P.D., Peeters P.H.M., Trichopoulou A., Fragogeorgi E., Oikonomou E., Boeing H., Schuetze M., Canzian F., Lukanova A., Tjonneland A., Roswall N., Overvad K., Weiderpass E., Gram I.T., Lund E., Lindkvist B., Johansen D., Ye W., Sund M., Fedirko V., Jenab M., Michaud D.S., Riboli E., and Bueno-de-Mesquita H.B. Menstrual and reproductive factors in women, genetic variation in CYP17A1, and pancreatic cancer risk in the European prospective investigation into cancer and nutrition (EPIC) cohort. [2013] International Journal of Cancer (132) 9 : 2164-2175. Impact factor : 5.007 [17] Dumay A., Feugeas J.P., Wittmer E., Lehmann-Che J., Bertheau P., Espié M., Plassa L.F., Cottu P., Marty M., André F., Sotiriou C., Pusztai L., and De Thé H. Distinct tumor protein p53 mutants in breast cancer subgroups. [2013] International Journal of Cancer. Impact factor : 5.007 [18] Fagherazzi G., Vilier A., Balkau B., Clavel-Chapelon F., and Ma� gliano D.J. Anthropometrics, body shape over 12 years and risk of cancer events in pre- and post-menopausal women. [2013] International Journal of Cancer (133) 3 : 740-748. Impact factor : 5.007 [19] Kühn T., Kaaks R., Becker S., Eomois P.P., Clavel-Chapelon F., Kvaskoff M., Dossus L., Tjonneland A., Olsen A., Overvad K., Chang-Claude J., Lukanova A., Buijsse B., Boeing H., Trichopoulou A., Lagiou P., Bamia C., Masala G., Krogh V., Sacerdote C., Tumino R., Mattiello A., Buckland G., Sanchez M.J., Menendez V., Chirlaque M.D., Barricarte A., Bueno-de-Mesquita H.B., Van Duijnhoven F.J.B., Van Gils C.H., Bakker M.F., Weiderpass E., Skeie G., Brustad M., Andersson A., Sund M., Wareham N., Khaw K.T., Travis R.C., Schmidt J.A., Rinaldi S., Romieu I., Gallo V., Murphy N., Riboli E., and Linseisen J. Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: A nested case-control study. [2013] International Journal of Cancer (133) 7 : 1689-1700. Impact factor : 5.007 [20] Ritte R., Lukanova A., Tjonneland A., Olsen A., Overvad K., Mesrine S., Fagherazzi G., Dossus L., Teucher B., Steindorf K., Boeing H., Aleksandrova K., Trichopoulou A., Lagiou P., Trichopoulos D., Palli D., Grioni S., Mattiello A., Tumino R., Sacerdote C., Quiros J.R., Buckland G., Molina-Montes E., Chirlaque M.D., Ardanaz 08 annexes rapport annuel / Gustave Roussy 2013 E., Amiano P., Bueno-de-Mesquita B., van Duijnhoven F., Van Gils C.H., Peeters P.H., Wareham N., Khaw K.T., Key T.J., Travis R.C., Krum-Hansen S., Gram I.T., Lund E., Sund M., Andersson A., Romieu I., Rinaldi S., Mccormack V., Riboli E., and Kaaks R. Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: A cohort study. [2013] International Journal of Cancer. Impact factor : 5.007 [21] Rohrmann S., Linseisen J., Nöthlings U., Overvad K., Egeberg R., Tjonneland A., Boutron-Ruault M.C., Clavel-Chapelon F., Cottet V., Pala V., Tumino R., Palli D., Panico S., Vineis P., Boeing H., Pischon T., Grote V., Teucher B., Khaw K.T., Wareham N.J., Crowe F.L., Goufa I., Orfanos P., Trichopoulou A., Jeurnink S.M., Siersema P.D., Peeters P.H.M., Brustad M., Engeset D., Skeie G., Duell E.J., Amiano P., Barricarte A., Molina-Montes E., Rodriguez L., Tormo M.J., Sund M., Ye W., Lindkvist B., Johansen D., Ferrari P., Jenab M., Slimani N., Ward H., Riboli E., Norat T., and Bueno-de-Mesquita H.B. Meat and fish consumption and risk of pancreatic cancer: Results from the European Prospective Investigation into Cancer and Nutrition. [2013] International Journal of Cancer (132) 3 : 617-624. Impact factor : 5.007 [22] Schlesinger S., Aleksandrova K., Pischon T., Fedirko V., Jenab M., Trepo E., Boffetta P., Dahm C.C., Overvad K., Tjonneland A., Halkjaer J., Fagherazzi G., Boutron-Ruault M.C., Carbonnel F., Kaaks R., Lukanova A., Boeing H., Trichopoulou A., Bamia C., Lagiou P., Palli D., Grioni S., Panico S., Tumino R., Vineis P., Bueno-de-Mesquita H.B., van den Berg S., Peeters P.H.M., Braaten T., Weiderpass E., Quiros J.R., Travier N., Sanchez M.J., Navarro C., Barricarte A., Dorronsoro M., Lindkvist B., Regner S., Werner M., Sund M., Khaw K.T., Wareham N., Travis R.C., Norat T., Wark P.A., Riboli E., and Nöthlings U. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. [2013] International Journal of Cancer (132) 3 : 645-657. Impact factor : 5.007 [23] Steindorf K., Ritte R., Eomois P.P., Lukanova A., Tjonneland A., Johnsen N.F., Overvad K., Ostergaard J.N., Clavel-Chapelon F., Fournier A., Dossus L., Teucher B., Rohrmann S., Boeing H., Wientzek A., Trichopoulou A., Karapetyan T., Trichopoulos D., Masala G., Berrino F., Mattiello A., Tumino R., Ricceri F., Quiros J., Travier N., Sanchez M.J., Navarro C., Ardanaz E., Amiano P., Bueno-de-Mesquita H., van Duijnhoven F., Monninkhof E., May A.M., Khaw K.T., Wareham N., Key T.J., Travis R.C., Borch K.B., Sund M., Andersson A., Fedirko V., Rinaldi S., Romieu I., Wahrendorf J., Riboli E., and Kaaks R. Physical activity and risk of breast cancer overall and by hormone receptor status: The European prospective investigation into cancer and nutrition. [2013] International Journal of Cancer. Impact factor : 5.007 [24] Ten Hagen T.L., Seynhaeve A.L., De Wiel-Ambagtsheer G.A., De Bruijn E.A., Van Tiel S.T., Ruegg C., Meyring M., Grell M., Goodman S.L., and Eggermont A.M. The aVß3/aVß5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model. [2013] International Journal of Cancer (132) 11 : 2694-2704. Impact factor : 5.007 [25] Zamora-Ros R., Fedirko V., Trichopoulou A., Gonzalez C.A., Bamia C., Trepo E., Nöthlings U., Duarte-Salles T., Serafini M., Bredsdorff L., Overvad K., Tjonneland A., Halkjaer J., Fagherazzi G., Perquier F., Boutron-Ruault M.C., Katzke V., Lukanova A., Floegel A., Boeing H., Lagiou P., Trichopoulos D., Saieva C., Agnoli C., Mattiello A., Tumino R., Sacerdote C., Bueno-de-Mesquita H.B., Peeters P.H.M., Weiderpass E., Engeset D., Skeie G., Argüelles M.V., Molina-Montes E., Dorronsoro M., Tormo M.J., Ardanaz E., Ericson U., Sonestedt E., Sund M., Landberg R., Khaw K.T., Wareham N.J., Crowe F.L., Riboli E., and Jenab M. Dietary flavonoid, lignan and antioxidant capacity and risk of hepatocellular carcinoma in the European prospective investigation into cancer and nutrition study. [2013] International Journal of Cancer (133) 10 : 2429-2443. Impact factor : 5.007 [26] Benusiglio P.R., Caron O., Consolino E., Duvillard P., Coulet F., Blayau M., and Malka D. Cleft lip, cleft palate, hereditary diffuse gastric cancer and germline mutations in CDH1. [2013] International Journal of Cancer. Impact factor : 5.007 [27] Droin N., Guéry L., Benikhlef N., and Solary E. Targeting apoptosis proteins in hematological malignancies. [2013] Cancer Letters (332) 2 : 325-334. Impact factor : 5.016 [28] Opletalova K., Bourrillon A., Yang W., Pouvelle C., Armier J., Despras E., Martin L., Mateus C., Robert C., Kannouche P., Soufir N., and Sarasin A. Correlation of Phenotype/Genotype in a Cohort of 23 Xeroderma Pigmentosum-Variant Patients Reveals 12 New Disease-Causing POLH Mutations. [2013] Human mutation. Impact factor : 5.050 [29] Soltys D.T., Rocha C.R.R., Lerner L.K., de Souza T.A., Munford V., Cabral F., Nardo T., Stefanini M., Sarasin A., Cabral-Neto J.B., and Menck C.F.M. Novel XPG (ERCC5) Mutations Affect DNA Repair and Cell Survival after Ultraviolet but not Oxidative Stress. [2013] Human mutation (34) 3 : 481-489. Impact factor : 5.050 [30] Baltar V.T., Xun W.W., Johansson M., Ferrari P., Chuang S.C., Relton C., Ueland P.M., Midttun O., Slimani N., Jenab M., Clavel-Chapelon F., Boutron-Ruault M.C., Fagherazzi G., Kaaks R., Rohrmann S., Boeing H., Weikert C., Bueno-de-Mesquita B., Boshuizen H., Van Gils C.H., Onland-Moret N.C., Agudo A., Barricarte A., Navarro C., Rodriguez L., Castano J.M.H., Larranaga N., Khaw K.T., Wareham N., Allen N.E., Crowe F., Gallo V., Norat T., Krogh V., Masala G., Panico S., Sacerdote C., Tumino R., Trichopoulou A., Lagiou P., Trichopoulos D., Rasmuson T., Hallmans G., Roswall N., Tjonneland A., Riboli E., Brennan P., and Vineis P. A structural equation modelling approach to explore the role of B vitamins and immune markers in lung cancer risk. [2013] European Journal of Epidemiology (28) 8 : 677-688. Impact factor : 5.147 [31] Bamia C., Lagiou P., Buckland G., Grioni S., Agnoli C., Taylor A.J., Dahm C.C., Overvad K., Olsen A., Tjonneland A., Cottet V., Boutron-Ruault M.C., Morois S., Grote V., Teucher B., Boeing H., Buijsse B., Trichopoulos D., Adarakis G., Tumino R., Naccarati A., Panico S., Palli D., Bueno-de-Mesquita H.B., Van Duijnhoven F.J.B., Peeters P.H.M., Engeset D., Skeie G., Lund E., Sanchez M.J., Barricarte A., Huerta J.M., Quiros J.R., Dorronsoro M., Ljuslinder I., Palmqvist R., Drake I., Key T.J., Khaw K.T., Wareham N., Romieu I., Fedirko V., Jenab M., Romaguera D., Norat T., and Trichopoulou A. Mediterranean diet and colorectal cancer risk: Results from a European cohort. [2013] European Journal of Epidemiology (28) 4 : 317-328. Impact factor : 5.147 [32] Troncose Baltar V., Johansson M., Ferrari P., Chuang S.C., Relton C., Ueland P.M., Midttun O., Slimani N., Jenab M., Clavel-Chapelon F., Boutron-Ruault M.C., and Faghe Vineis P. A structural equation modelling approach to explore the role of B vitamins and immune markers in lung cancer risk. [2013] European Journal of Epidemiology (28) 8 : 677-688. Impact factor : 5.147 [33] Ali A., Bluteau O., Messaoudi K., Palazzo A., Boukour S., Lordier L., Lecluse Y., Rameau P., Kraus-Berthier L., Jacquet-Bescond A., Lelièvre H., Depil S., Dessen P., Solary E., Raslova H., Vainchenker W., Plo I., and Debili N. Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and-independent mechanisms. [2013] Cell Death and Disease (4) 7. Impact factor : 5.177 [34] Habel N., Hamidouche Z., Girault I., Patino-Garcia A., Lecanda F., Marie P.J., and Fromigué O. Zinc chelation: A metallothionein 2A’s mechanism of action involved in osteosarcoma cell death and chemotherapy resistance. [2013] Cell Death and Disease (4) 10 : e874-e874. Impact factor : 5.177 [35] Bonichon F., Palussière J., Godbert Y., Pulido M., Descat E., Devillers A., Meunier C., Leboulleux S., DeBaère T., Galy-Lacour C., Lagoarde-Segot L., and Cazeau A.L. Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: A multicentre prospective study. [2013] European Journal of Nuclear Medicine and Molecular Imaging (40) 12 : 1817-1827. Impact factor : 5.217 [36] Agudo A., Bonet C., Sala N., Munoz X., Aranda N., Fonseca-Nunes A., Clavel-Chapelon F., Boutron-Ruault M.C., Vineis P., Panico S., Palli D., Tumino R., Grioni S., Quiros J.R., Molina E., Navarro C., Barricarte A., Chamosa S., Allen N.E., Khaw K.T., Bueno-de-Mesquita H.B., Siersema P.D., Numans M.E., Trichopoulou A., Lagiou P., Trichopoulos D., Kaaks R., Canzian F., Boeing H., Meidtner K., Johansson M., Sund M., Manjer J., Overvad K., Tjonneland A., Lund E., Weiderpass E., Jenab M., Fedirko V., Offerhaus G.J., Riboli E., Gonzalez C.A., and Jakszyn P. Hemochromatosis (HFE) gene mutations and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. [2013] Carcinogenesis (34) 6 : 1244-1250. Impact factor : 5.266 [37] Castro-Vega L.J., Jouravleva K., Liu W.Y., Martinez C., Gestraud P., Hupé P., Servant N., Albaud B., Gentien D., Gad S., Richard S., Bacchetti S., and Londono-Vallejo A. Telomere crisis in kidney epithelial cells promotes the acquisition of a microRNA signature retrieved in aggressive renal cell carcinomas. [2013] Carcinogenesis (34) 5 : 1173-1180. Impact factor : 5.266 [38] Calaminus G., Kortmann R., Worch J., Nicholson J.C., Alapetite C., Garrè M.L., Patte C., Ricardi U., Saran F., and Frappaz D. SIOP CNS GCT 96: Final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for pat. [2013] Neuro-Oncology (15) 6 : 788-796. Impact factor : 5.286 [39] Grill J., Geoerger B., Gesner L., Perek D., Leblond P., Canete A., Aerts I., Madero L., De Toledo Codina J.S., Verlooy J., Estlin E., Cisar L., Breazna A., Dorman A., Bailey S., Nicolin G., Grundy R.G., and Hargrave D. Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: A joint ITCC and SIOPE brain tumor study. [2013] Neuro-Oncology (15) 9 : 1236-1243. Impact factor : 5.286 [40] Favier R., Feriel J., Favier M., Denoyelle F.o., and Martignetti J.A. First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia. [2013] Pediatrics (132) 3 : e793-e795. Impact factor : 5.297 Gustave Roussy 2013 / annexes rapport annuel 09 [41] Lagrange B., Martin R.Z., Droin N., Aucagne R., Paggetti J., Largeot A., Itzykson R., Solary E., Delva L., and Bastie J.N. A role for miR-142-3p in colony-stimulating factor 1-induced monocyte differentiation into macrophages. [2013] Biochimica et Biophysica Acta - Molecular Cell Research (1833) 8 : 1936-1946. Impact factor : 5.297 [42] Hasmim M., Noman M.Z., Messai Y., Bordereaux D., Gros G., Baud V., and Chouaib S. Cutting edge: Hypoxia-induced nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-ß1. [2013] Journal of Immunology (191) 12 : 5802-5806. Impact factor : 5.362 [43] Seach N., Guerri L., Le Bourhis L., Mburu Y., Cui Y., Bessoles S., Soudais C., and Lantz O. Double positive thymocytes select mucosal-associated invariant T cells. [2013] Journal of Immunology (191) 12 : 6002-6009. Impact factor : 5.362 [44] Albanesi M., Mancardi D.A., Macdonald L.E., Iannascoli B., Zitvogel L., Murphy A.J., Daëron M., Leusen J.H., and Bruhns P. Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517)). [2013] Journal of Immunology (190) 3 : 1381-1381. Impact factor : 5.362 [45] Jacquier H., Marcadé G., Raffoux E., Dombret H., Woerther P.L., Donay J.L., Arlet G., and Cambau E. In vivo selection of a complex mutant TEM (CMT) from an inhibitor-resistant TEM (IRT) during ceftazidime therapy. [2013] Journal of Antimicrobial Chemotherapy (68) 12 : 2792-2796 . Impact factor : 5.439 [46] Kaguelidou F., Amiel P., Blachier A., Iliescu C., Rozé J.C., Tsimaratos M., Brandt C., Kassai-Koupai B., Jacqz-Aigrain E., Gaultier C., and Alberti C. Recruitment in pediatric clinical research was influenced by study characteristics and pediatricians’ perceptions: A multicenter survey. [2013] Journal of Clinical Epidemiology (66) 10 : 1151-1157. Impact factor : 5.478 [47] Thuringer D., Jego G., Wettstein G., Terrier O., Cronier L., Yousfi N., Hébrard S., Bouchot A., Hazoumé A., Joly A.L., Gleave M., Rosa-Calatrava M., Solary E., and Garrido C. Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3. [2013] FASEB Journal (27) 10 : 4169-4183. Impact factor : 5.480 [48] Berrou E., Adam F., Lebret M., Fergelot P., Kauskot A., Coupry I., Jandrot-Perrus M., Nurden A., Favier R., Rosa J.P., Goizet C., Nurden P., and Bryckaert M. Heterogeneity of platelet functional alterations in patients with filamin A mutations. [2013] Arteriosclerosis, thrombosis, and vascular biology (33) 1 : e11-e18. Impact factor : 5.533 [49] Lopez J.J., Palazzo A., Chaabane C., Albarran L., Polidano E., Lebozec K., Dally S., Nurden P., Enouf J., Debili N., and Bobe R. Crucial role for endoplasmic reticulum stress during megakaryocyte maturation. [2013] Arteriosclerosis, thrombosis, and vascular biology (33) 12 : 2750-2758. Impact factor : 5.533 [50] Chalumeau-Lemoine L., Stoclin A., Billard V., Laplanche A., Raynard B., and Blot F. Flexible fiberoptic bronchoscopy and remifentanil target-controlled infusion in ICU: a preliminary study. [2013] Intensive Care Medicine. Impact factor : 5.544 [51] Bellesoeur A., Chalumeau-Lemoine L., and Blot F. Excavated pneumonia: An unusual suspect. [2013] Intensive Care Medicine (39) 7 : 1318-1319. Impact factor : 5.544 [52] Bluteau O., Langlois T., Rivera-Munoz P., Favale F., Rameau P., 10 annexes rapport annuel / Gustave Roussy 2013 Meurice G., Dessen P., Solary E., Raslova H., Mercher T., Debili N., and Vainchenker W. Developmental changes in human megakaryopoiesis. [2013] Journal of Thrombosis and Haemostasis (11) 9 : 1730-1741. Impact factor : 5.550 [53] Chen Y., Boukour S., Milloud R., Favier R., Saposnik B., Schlegel N., Nurden A., Raslova H., Vainchenker W., Balland M., Nurden P., and Debili N. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition. [2013] Journal of Thrombosis and Haemostasis (11) 12 : 21632175. Impact factor : 5.550 [54] Benusiglio P.R., Malka D., Rouleau E., Pauw A.D., Buecher B., Noguès C., Fourme E., Colas C., Coulet F., Warcoin M., Grandjouan S., Sezeur A., Laurent-Puig P., Molière D., Tlemsani C., Maria M.D., Byrde V., Delaloge S., Blayau M., and Caron O. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: A multicentre study. [2013] Journal of Medical Genetics (50) 7 : 486-489. Impact factor : 5.636 [55] Bubien V., Bonnet F., Brouste V., Hoppe S., Barouk-Simonet E., David A., Edery P., Bottani A., Layet V., Caron O., Gilbert-Dussardier B., Delnatte C., Dugast C., Fricker J.P., Bonneau D., Sevenet N., Longy M., and Caux F. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. [2013] Journal of Medical Genetics (50) 4 : 255-263. Impact factor : 5.636 [56] Puntervoll H.E., Yang X.R., Vetti H.H., Bachmann I.M., Avril M.F., Benfodda M., Catricala C., Dalle S., Duval-Modeste A.B., Ghiorzo P., Grammatico P., Harland M., Hayward N.K., Hu H.H., Jouary T., Martin-Denavit T., Ozola A., Palmer J.M., Pastorino L., Pjanova D., Soufir S., Steine S.J., Stratigos A.J., Thomas L., Tinat J., Tsao H., Veinalde R., Tucker M.A., Paillerets B.B., Newton-Bishop J.A., Goldstein A.M., Akslen L.A., and Molven A. Melanoma prone families with CDK4 germline mutation: Phenotypic profile and associations with MC1R variants. [2013] Journal of Medical Genetics (50) 4 : 264-270. Impact factor : 5.636 [57] Ghiorzo P., Pastorino L., Queirolo P., Bruno W., Tibiletti M.G., Nasti S., Andreotti V., Paillerets B.B., and Bianchi Scarra G. Prevalence of the E318K MITF germline mutation in Italian melanoma patients: Associations with histological subtypes and family cancer history. [2013] Pigment Cell and Melanoma Research (26) 2 : 259-262. Impact factor : 5.641 [58] Norkowski E., Ghigna M.R., Lacroix L., Le Chevalier T., Fadel E., Dartevelle P., Dorfmuller P., and Thomas de Montpréville V. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology. [2013] Journal of thoracic oncology (8) 10 : 1265-1271. Impact factor : 5.800 [59] Ramaekers B.L.T., Joore M.A., Lueza B., Bonastre J., Mauguen A., Pignon J.P., Le Pechoux C., De Ruysscher D.K.M., Grutters J.P.C., Arriagada R., Bae K., Ball D., Baumann M., Behrendt K., Belani C.P., Beresford J., Bishop J., Bonner J.A., Choy H., Dahlberg S.E., De Ruysscher D., Dische S., Fournel P., Koch R., Le Péchoux C., Mandrekar S.J., Mauguen A., Mornex F., Nankivell M., Nelson G., Parmar M.K., Paulus R., Pignon J.P., Saunders M.I., Sause W., Schild S.E., Turrisi A.T., and Zajusz A. Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non-Small-Cell Lung Cancer Patients. [2013] Journal of thoracic oncology (8) 10 : 1295-1307. Impact factor : 5.800 [60] Scagliotti G.V., Felip E., Besse B., von Pawel J., Mellemgaard A., Reck M., Bosquee L., Chouaid C., Lianes-Barragan P., Paul E.M., Ruiz-Soto R., Sigal E., Ottesen L.H., and Lechevalier T. An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer. [2013] Journal of thoracic oncology (8) 12 : 1529-1537. Impact factor : 5.800 [61] Bachy E., Houot R., Morschhauser F., Sonet A., Brice P., Belhadj K., Cartron G., Audhuy B., Fermé C., Feugier P., Sebban C., Delwail V., Maisonneuve H., Le Gouill S., Lefort S., Brousse N., Foussard C., and Salles G. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. [2013] Haematologica (98) 7 : 1107-1114. Impact factor : 5.868 [62] Charrier S., Blundell M., Cédrone G., Louache F., Vainchenker W., Thrasher A.J., and Galy A. Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor. [2013] Haematologica (98) 8 : 1300-1308. Impact factor : 5.868 [63] Coman T., Bachy E., Michallet M., Socié G., Uzunov M., Bourhis J.H., Lapusan S., Brebion A., Vigouroux S., Maury S., François S., Huynh A., Lioure B., Yakoub-Agha I., Hermine O., Milpied N., Mohty M., and Rubio M.T. Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: A report from the French Society of Bone Marrow and Cellular Therapy. [2013] Haematologica (98) 5 : 776-783. Impact factor : 5.868 [64] Couronné L., Scourzic L., Pilati C., Valle V.D., Duffourd Y., Solary E., Vainchenker W., Merlio J.P., Beylot-Barry M., Damm F., Stern M.H., Gaulard P., Lamant L., Delabesse E., Merle-Beral H., Nguyen-Khac F., Fontenay M., Tilly H., Bastard C., Zucman-Rossi J., Bernard O.A., and Mercher T. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. [2013] Haematologica (98) 11 : 1748-1752. Impact factor : 5.868 [65] Marcais A., Porcher R., Robin M., Mohty M., Michalet M., Blaise D., Tabrizi R., Clement L., Ceballos P., Daguindau E., Bilger K., Dhedin N., Lapusan S., Bay J.O., Pautas C., Garban F., Ifrah N., Guillerm G., Contentin N., Bourhis J.H., Agha I.Y., Bernard M., Cornillon J., and Milpied N. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin’s lymphoma: A retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). [2013] Haematologica (98) 9 : 1467-1475. Impact factor : 5.868 [66] Oschlies I., Lisfeld J., Lamant L., Nakazawa A., D’Amore E.S.G., Hansson U., Hebeda K., Simonitsch-Klupp I., Maldyk J., Müllauer L., Tinguely M., Stücker M., LeDeley M.C., Siebert R., Reiter A., Brugières L., Klapper W., and Woessmann W. ALK-positive anaplastic large cell lymphoma limited to the skin: Clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. [2013] Haematologica (98) 1 : 50-56. Impact factor : 5.868 [67] Ribrag V., Caballero D., Fermé C., Zucca E., Arranz R., Briones J., Gisselbrecht C., Salles G., Gianni A.M., Gomez H., Kahatt C., Corrado C., Szyldergemajn S., Extremera S., de Miguel B., Cullell-Young M., and Cavalli F. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma. [2013] Haematologica (98) 3 : 357-363. Impact factor : 5.868 [68] Van Den Neste E., Casasnovas O., André M., Touati M., Senecal D., Edeline V., Stamatoullas A., Fornecker L., Deau B., Gastinne T., Reman O., Gaillard I., Borel C., Brice P., and Fermé C. Classical Hodgkin’s lymphoma: The Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. [2013] Haematologica (98) 8 : 1185-1195. Impact factor : 5.868 [69] Coppo P. Response to “predictors of survival in thrombotic thrombocytopenic purpura” Haematologica. [2013] Haematologica (98) 7 : e58-e58. Impact factor : 5.868 [70] Repunte-Canonigo V., Chen J., Lefebvre C., Kawamura T., Kreifeldt M., Basson O., Roberts A.J., and Sanna P.P. MeCP2 regulates ethanol sensitivity and intake. [2013] Addiction Biology. Impact factor : 5.929 [71] Mittempergher L., Saghatchian M., Wolf D.M., Michiels S., Canisius S., Dessen P., Delaloge S., Lazar V., Benz S.C., Tursz T., Bernards R., and van’t Veer L.J. A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. [2013] Molecular Oncology (7) 5 : 987-999. Impact factor : 5.935 [72] Carton E., Bellesoeur A., and Mir O. Colony-stimulating factors for febrile neutropenia. [2013] New England Journal of Medicine (369) 3 : 285-286. Impact factor : 54.420 [73] Ferté C., Loriot Y., Clémenson C., Commo F., Gombos A., Bibault J.E., Fumagalli I., Hamama S., Auger N., Lahon B., Chargari C., Calderaro J., Soria J.C., and Deutsch E. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: An opportunity to increase the efficacy of standard therapy. [2013] Molecular Cancer Therapeutics (12) 7 : 12131222. Impact factor : 6.107 [74] Albi-Feldzer A., Mouret-Fourme E., Hamouda S., Motamed C., Dubois P.Y., Jouanneau L., and Jayr C. A double-blind randomized trial of wound and intercostal space infiltration with ropivacaine during breast cancer surgery: Effects on chronic postoperative pain. [2013] Anesthesiology (118) 2 : 318-326. Impact factor : 6.168 [75] Kvaskoff M., Bijon A., Clavel-Chapelon F., Mesrine S., and Boutron-Ruault M.C. Childhood and Adolescent Exposures and the Risk of Endometriosis. [2013] Epidemiology (24) 2 : 261-269. Impact factor : 6.178 [76] Mahnken A.H., Pereira P.L., and DeBaère T. Interventional oncologic approaches to liver metastases. [2013] Radiology (266) 2 : 407-430. Impact factor : 6.214 [77] Franco C.A., Blanc J., Parlakian A., Blanco R., Aspalter I.M., Kazakova N., Diguet N., Mylonas E., Gao-Li J., Vaahtokari A., Penard-Lacronique V., Fruttiger M., Rosewell I., Mericskay M., Gerhardt H., and Li Z. SRF selectively controls tip cell invasive behavior in angiogenesis. [2013] Development (140) 11 : 23212333. Impact factor : 6.273 [78] Aranda F., Vacchelli E., Eggermont A., Galon J., Sautès-Fridman C., Tartour E., Zitvogel L., Kroemer G., and Galluzzi L. Gustave Roussy 2013 / annexes rapport annuel 11 Trial Watch: Peptide vaccines in cancer therapy. [2013] Oncoimmunology (2) 12 : e26621-e26621. Impact factor : 6.283 [79] Menger L., Vacchelli E., Kepp O., Eggermont A., Tartour E., Zitvogel L., Kroemer G., and Galluzzi L. Trial watch: Cardiac glycosides and cancer therapy. [2013] Oncoimmunology (2) 2. Impact factor : 6.283 [80] Semeraro M., Vacchelli E., Eggermont A., Galon J., Zitvogel L., Kroemer G., and Galluzzi L. Trial Watch: Lenalidomide-based immunochemotherapy. [2013] Oncoimmunology (2) 11 : e26494-e26494. Impact factor : 6.283 [81] Senovilla L., Vacchelli E., Garcia P., Eggermont A., Fridman W.H., Galon J., Zitvogel L., Kroemer G., and Galluzzi L. Trial watch: DNA vaccines for cancer therapy. [2013] Oncoimmunology (2) 4. Impact factor : 6.283 [82] Vacchelli E., Eggermont A., Fridman C.S., Galon J., Zitvogel L., Kroemer G., and Galluzzi L. Trial watch: Oncolytic viruses for cancer therapy. [2013] Oncoimmunology (2) 6. Impact factor : 6.283 [83] Vacchelli E., Eggermont A., Fridman W.H., Galon J., Tartour E., Zitvogel L., Kroemer G., and Galluzzi L. Trial watch : Adoptive cell transfer for anticancer immunotherapy. [2013] Oncoimmunology (2) 5. Impact factor : 6.283 [84] Vacchelli E., Eggermont A., Fridman W.H., Galon J., Zitvoge L., Kroemer G., and Galluzzi L. Trial watch: Immunostimulatory cytokines. [2013] Oncoimmunology (2) 7. Impact factor : 6.283 [85] Vacchelli E., Eggermont A., Sautès-Fridman C., Galon J., Zitvogel L., Kroemer G., and Galluzzi L. Trial watch : Toll-like receptor agonists for cancer therapy. [2013] Oncoimmunology (2) 8. Impact factor : 6.283 [86] Vacchelli E., Senovilla L., Eggermont A., Fridman W.H., Galon J., Zitvogel L., Kroemer G., and Galluzzi L. Trial watch: Chemotherapy with immunogenic cell death inducers. [2013] Oncoimmunology (2) 3. Impact factor : 6.283 [87] Vacchelli E., Vitale I., Eggermont A., Fridman W.H., Fuaakova J., Cremer I., Galon J., Tartour E., Zitvogel L., Kroemer G., and Galluzzi L. Trial Watch: Dendritic cell-based interventions for cancer therapy. [2013] Oncoimmunology (2) 10. Impact factor : 6.283 [88] Vacchelli E., Vitale I., Tartour E., Eggermont A., Sautès-Fridman C., Galon J., Zitvogel L., Kroemer G., and Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. [2013] Oncoimmunology (2) 9 : e25595-e25595. Impact factor : 6.283 [89] Chaput N., Flament C., Locher C., Desbois M., Rey A., Rusakiewicz S., Poirier-Colame V., Pautier P., Le Cesne A., Soria J.C., Paci A., Rosenzwajg M., Klatzmann D., Eggermont A., Robert C., and Zitvogel L. Phase I clinical trial combining imatinib mesylate and IL-2 HLA-DR+ NK cell levels correlate with disease outcome. [2013] Oncoimmunology (2) 2 : e23080-e23080. Impact factor : 6.283 [90] Galluzzi L. and Lugli E. Cancer immunotherapy turns viral. [2013] Oncoimmunology (2) 4 : e24802-e24802. Impact factor : 6.283 [91] Galluzzi L., Kepp O., and Kroemer G. Immunogenic cell death in radiation therapy. [2013] Oncoimmunology (2) 10 : e26536-e26536. Impact factor : 6.283 [92] Kroemer G., Zitvogel L., and Galluzzi L. Victories and deceptions in tumor immunology: Stimuvax®. [2013] Oncoimmunology (2) 1 : e23687-e23687. Impact factor : 6.283 12 annexes rapport annuel / Gustave Roussy 2013 [93] Ma Y., Adjemian S., Yang H., Catani J.P.P., Hannani D., Martins I., Michaud M., Kepp O., Sukkurwala A.Q., Vacchelli E., Galluzzi L., Zitvogel L., and Kroemer G. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. [2013] Oncoimmunology (2) 6. Impact factor : 6.283 [94] Ma Y., Yamazaki T., Yang H., Kepp O., Galluzzi L., Zitvogel L., Smyth M.J., and Kroemer G. Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. [2013] Oncoimmunology (2) 6. Impact factor : 6.283 [95] Mavilio D., Galluzzi L., and Lugli E. Novel multifunctional antibody approved for the treatment of breast cancer. [2013] Oncoimmunology (2) 6. Impact factor : 6.283 [96] Pautier P., Locher C., Robert C., Deroussent A., Flament C., Le Cesne A., Rey A., Bahleda R., Ribrag V., Soria J.C., Vassal G., Eggermont A., Zitvogel L., Chaput N., and Paci A. Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate. [2013] Oncoimmunology (2) 2 : e23079-e23079. Impact factor : 6.283 [97] Prada N., Antoni G., Commo G., Rusakiewicz S., Semeraro M., Boufassa F., Lambotte O., Meyer L., Lise M.G., and Zitvogel L. Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. [2013] Oncoimmunology (2) 3 : e23472-e23472. Impact factor : 6.283 [98] Senovilla L., Vitale I., Martins I., Kepp O., Galluzzi L., Zitvoge L., Castedo M., and Kroemer G. An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells. [2013] Oncoimmunology (2) 1. Impact factor : 6.283 [99] Tabbekh M., Mokrani-Hammani M., Bismuth G., and MamiChouaib F. T-cell modulatory properties of CD5 and its role in antitumor immune responses. [2013] Oncoimmunology (2) 1. Impact factor : 6.283 [100] Zitvogel L., Tanchot C., Granier C., and Tartour E. Following up tumor-specific regulatory T cells in cancer patients. [2013] Oncoimmunology (2) 7. Impact factor : 6.283 [101] Galluzzi L. New immunotherapeutic paradigms for castration-resistant prostate cancer. [2013] Oncoimmunology (2) 8 : e26084-e26084. Impact factor : 6.283 [102] Galluzzi L. and Lugli E. Rejuvenated T cells attack old tumors. [2013] Oncoimmunology (2) 2 : e24103-e24103. Impact factor : 6.283 [103] Kepp O., Galluzzi L., and Kroemer G. Immune effectors required for the therapeutic activity of vorinostat. [2013] Oncoimmunology (2) 11 : e27157-e27157. Impact factor : 6.283 [104] Kroemer G., Galluzzi L., and Zitvogel L. Immunological effects of chemotherapy in spontaneous breast cancers. [2013] Oncoimmunology (2) 12 : e27158-e27158. Impact factor : 6.283 [105] Vacchelli E., Prada N., Kepp O., and Galluzzi L. Current trends of anticancer immunochemotherapy. [2013] Oncoimmunology (2) 6. Impact factor : 6.283 [106] Vacchelli E., Eggermont A., Galon J., Sautès-Fridman C., Zitvogel L., Kroemer G., and Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. [2013] Oncoimmunology (2) 1. Impact factor : 6.283 [107] Dewannieux M. and Heidmann T. Endogenous retroviruses: Acquisition, amplification and taming of genome invaders. [2013] Current Opinion in Virology (3) 6 : 646-656. Impact factor : 6.298 [108] De Martino M.C., Al Ghuzlan A., Aubert S., Assié G., Scoazec J.Y., Leboulleux S., Do Cao C., Libè R., Nozières C., Lombès M., Pattou F., Borson-Chazot F., Hescot S., Mazoyer C., Young J., Borget I., Colao A., Pivonello R., Soria J.C., Bertherat J., Schlumberger M., Lacroix L., and Baudin E. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. [2013] Journal of Clinical Endocrinology and Metabolism (98) 10 : 40804088. Impact factor : 6.310 [109] Elowe-Gruau E., Beltrand J., Brauner R., Pinto G., Samara-Boustani D., Thalassinos C., Busiah K., Laborde K., Boddaert N., Zerah M., Alapetite C., Grill J., Touraine P., Sainte-Rose C., Polak M., and Puget S. Childhood craniopharyngioma: Hypothalamus-sparing surgery decreases the risk of obesity. [2013] Journal of Clinical Endocrinology and Metabolism (98) 6 : 23762382. Impact factor : 6.310 [110] Gimenez-Roqueplo A.P., Caumont-Prim A., Houzard C., Hignette C., Hernigou A., Halimi P., Niccoli P., Leboulleux S., Amar L., Borson-Chazot F., Cardot-Bauters C., Delemer B., Chabolle F., Coupier I., Libè R., Peitzsch M., Peyrard S., Tenenbaum F., Plouin P.F., Chatellier G., and Rohmer V. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: A multicenter prospective study from the PGL.EVA investigators. [2013] Journal of Clinical Endocrinology and Metabolism (98) 1 : E162-E173. Impact factor : 6.310 [111] Hescot S., Leboulleux S., Amar L., Vezzosi D., Borget I., Bournaud-Salinas C., De La Fouchardiere C., Libè R., Do Cao C., Niccoli P., Tabarin A., Raingeard I., Chougnet C., Giraud S., Gimenez-Roqueplo A.P., Young J., Borson-Chazot F., Bertherat J., Wemeau J.L., Bertagna X., Plouin P.F., Schlumberger M., and Baudin E. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. [2013] Journal of Clinical Endocrinology and Metabolism (98) 10 : 4006-4012. Impact factor : 6.310 [112] Kerkhofs T.M., Baudin E., Terzolo M., Allolio B., Chadarevian R., Mueller H.H., Skogseid B., Leboulleux S., Mantero F., Haak H.R., and Fassnacht M. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. [2013] Journal of Clinical Endocrinology and Metabolism (98) 12 : 4759-4767. Impact factor : 6.310 [113] Massicotte M.H., Borget I., Broutin S., Baracos V.E., Leboulleux S., Baudin E., Paci A., Deroussent A., Schlumberger M., and Antoun S. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: Results from a placebo-controlled study. [2013] Journal of Clinical Endocrinology and Metabolism (98) 6 : 2401-2408. Impact factor : 6.310 [114] Tisset H., Kamar N., Faugeron I., Roy P., Pouteil-Noble C., Klein M., Mourad G., Drui D., Do Cao C., Leenhardt L., Allix I., Bonichon F., Morelon E., Leboulleux S., Kelly A., Niccoli P., Toubert M.E., Frimat L., Vantyghem M.C., Bournaud C., Schlumberger M., and Borson-Chazot F. Is thyroid cancer recurrence risk increased after transplantation? [2013] Journal of Clinical Endocrinology and Metabolism (98) 10 : 3981-3988. Impact factor : 6.310 [115] Lavialle C., Cornelis G., Dupressoir A., Esnault C., Heidmann O., Vernochet C., and Heidmann T. Paleovirology of ‘syncytins’, retroviral env genes exapted for a role in placentation. [2013] Philosophical Transactions of the Royal Society B: Biological Sciences (368) 1626. Impact factor : 6.314 [116] Robin Y.M., Penel N., Pérot G., Neuville A., Vélasco V., RanchèreVince D., Terrier P., and Coindre J.M. Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors. [2013] Modern Pathology. Impact factor : 6.364 [117] Sekula P., Dunant A., Mockenhaupt M., Naldi L., Bouwes Bavinck J.N., Halevy S., Kardaun S., Sidoroff A., Liss Y., Schumacher M., and Roujeau J.C. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. [2013] Journal of Investigative Dermatology (133) 5 : 1197-1204. Impact factor : 6.372 [118] Bibault J.E., Fumagalli I., Ferté C., Chargari C., Soria J.C., and Deutsch E. Personalized radiation therapy and biomarker-driven treatment strategies: A systematic review. [2013] Cancer and Metastasis Reviews (32) 3-4 : 479-492. Impact factor : 6.449 [119] Heinemann V., Douillard J.Y., Ducreux M., and Peeters M. Targeted therapy in metastatic colorectal cancer - An example of personalised medicine in action. [2013] Cancer Treatment Reviews (39) 6 : 592-601. Impact factor : 6.466 [120] Martin L.A., André F., Campone M., Bachelot T., and Jerusalem G. MTOR inhibitors in advanced breast cancer: Ready for prime time? [2013] Cancer Treatment Reviews (39) 7 : 742-752. Impact factor : 6.466 [121] Bhoo-Pathy N., Uiterwaal C.S.P.M., Dik V.K., Jeurnink S.M., Bech B.H., Overvad K., Halkjaer J., Tjonneland A., Boutron-Ruault M., Fagherazzi G., Racine A., Katzke V.A., Li K., Boeing H., Floegel A., Androulidaki A., Bamia C., Trichopoulou A., Masala G., Panico S., Crosignani P., Tumino R., Vineis P., Peeters P.H.M., Gavrilyuk O., Skeie G., Weiderpass E., Duell E.J., Argüelles M., Molina-Montes E., Navarro C., Ardanaz E., Dorronsoro M., Lindkvist B., Wallström P., Sund M., Ye W., Khaw K., Wareham N., Key T.J., Travis R.C., Duarte-Salles T., Freisling H., Licaj I., Gallo V., Michaud D.S., Riboli E., and Bueno-de-Mesquita H.B. Intake of coffee, decaffeinated coffee, or tea does not affect risk for pancreatic cancer: Results from the european prospective investigation into nutrition and cancer study. [2013] Clinical Gastroenterology and Hepatology (11) 11 : 1486-1492. Impact factor : 6.534 [122] Kepp O., Menger L., Vacchelli E., Locher C., Adjemian S., Yamazaki T., Martins I., Sukkurwala A.Q., Michaud M., Senovilla L., Galluzzi L., Kroemer G., and Zitvogel L. Crosstalk between ER stress and immunogenic cell death. [2013] Cytokine and Growth Factor Reviews (24) 4 : 311-318. Impact factor : 6.537 [123] Giron-Michel J., Azzi S., Ferrini S., Chouaib S., Camussi G., Eid P., and Azzarone B. Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal homeostasis. [2013] Cytokine and Growth Factor Reviews (24) 1 : 13-22. Impact factor : 6.537 [124] Beyer J., Albers P., Altena R., Aparicio J., Bokemeyer C., Busch J., Cathomas R., Cavallin-Stahl E., Clarke N.W., Classen J., Cohn-Cedermark G., Dahl A.A., Daugaard G., De Giorgi U., De Santis M., De Wit M., Dewit R., Dieckmann K.P., Fenner M., Fizazi K., Flechon A., Fossa S.D., Germa Lluch J.R., Gietema J.A., Gillessen S., Giwercman A., Hartmann J.T., Heidenreich A., Hentrich M., Honecker F., Horwich A., Huddart R.A., Kliesch S., Kollmannsberger C., Krege S., Laguna M.P., Looijenga L.H.J., Lorch Gustave Roussy 2013 / annexes rapport annuel 13 A., Lotz J.P., Mayer F., Necchi A., Nicolai N., Nuver J., Oechsle K., Oldenburg J., Oosterhuis J.W., Powles T., Rajpert-De Meyts E., Rick O., Rosti G., Salvioni R., Schrader M., Schweyer S., Sedlmayer F., Sohaib A., Souchon R., Tandstad T., Winter C., and Wittekind C. Maintaining success, reducing treatment burden, focusing on survivorship: Highlights from the third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer. [2013] Annals of Oncology (24) 4 : 878-888. Impact factor : 6.578 [125] Chargari C., Soria J.C., and Deutsch E. Controversies and challenges regarding the impact of radiation therapy on survival. [2013] Annals of Oncology (24) 1 : 38-46. Impact factor : 6.578 [126] Couraud S., Cortot A.B., Greillier L., Gounant V., Mennecier B., Girard N., Besse B., Brouchet L., Castelnau O., Frappé P., Ferretti G.R., Guittet L., Khalil A., Lefebure P., Laurent F., Liebart S., Molinier O., Quoix E., Revel M.P., Stach B., Souquet P.J., Thomas P., Trédanie J., Lemarié E., Zalcman G., Barlès F., and Milleron B. From randomized trials to the clinic: Is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d’Oncologie de langue française. [2013] Annals of Oncology (24) 3 : 586-597. Impact factor : 6.578 [127] Querleu D., Ray-Coquard I., Classe J.M., Aucouturier J.S., Bonnet F., Bonnier P., Darai E., Devouassoux M., Gladieff L., Glehen O., Haie-Meder C., Joly F., Lécuru F., Lefranc J.P., Lhommé C., Morice P., Salengro A., Stoeckle E., Taieb S., Zeng Z.X., and Leblanc E. Quality indicators in ovarian cancer surgery: Report from the french society of gynecologic oncology (Société Française d’Oncologie Gynécologique, SFOG). [2013] Annals of Oncology (24) 11 : 2732-2739. Impact factor : 6.578 [128] Soria J.C., Mauguen A., Reck M., Sandler A.B., Saijo N., Johnson D.H., Burcoveanu D., Fukuoka M., Besse B., and Pignon J.P. Systematic review and meta-analysis of randomised, phase II/ III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. [2013] Annals of Oncology (24) 1 : 20-30. Impact factor : 6.578 [129] Azim H.A., Michiels S., Zagouri F., Delaloge S., Filipits M., Namer M., Neven P., Symmans W.F., Thompson A., André F., Loi S., and Swanton C. Utility of prognostic genomic tests in breast cancer practice: The impakt 2012 working group consensus statement. [2013] Annals of Oncology (24) 3 : 647-654. Impact factor : 6.578 [130] Besse B., Tsao L.C., Chao D.T., Fang Y., Soria J.C., Almokadem S., and Belani C.P. Phase Ib safety and pharmacokinetic study of volociximab, an anti-a5ß1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. [2013] Annals of Oncology (24) 1 : 92-96. Impact factor : 6.578 [131] Boussemart L., Routier E., Mateus C., Opletalova K., Sebille G., Kamsu-Kom N., Thomas M., Vagner S., Favre M., Tomasic G., Wechsler J., Lacroix L., and Robert C. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: A study of 42 patients. [2013] Annals of Oncology (24) 6 : 1691-1697. Impact factor : 6.578 [132] Coriat R., Dhooge M., Brezault C., Chaussade S., and Mir O. Blood pressure monitoring in patients receiving bevacizumab. [2013] Annals of Oncology (24) 4 : 1127-1127. Impact factor : 6.578 [133] Delyon J., Mateus C., Lefeuvre D., Lanoy E., Zitvogel L., Chaput N., 14 annexes rapport annuel / Gustave Roussy 2013 Roy S., Eggermont A.M.M., Routier E., and Robert C. Experience in daily practice with ipilimumab for thetreatment of patients with metastatic melanoma: Anearly increase in lymphocyte and eosinophil countsis associated with improved survival. [2013] Annals of Oncology (24) 6 : 1697-1703. Impact factor : 6.578 [134] Deutsch E., Lemanski C., Pignon J.P., Levy A., Delarochefordiere A., Martel-Lafay I., Rio E., Malka D., Conroy T., Miglianico L., Becouarn Y., Malekzadeh K., Paris E., Juzyna B., Ezra P., and Azria D. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Results of the UNICANCER ACCORD 16 phase II trial. [2013] Annals of Oncology (24) 11 : 2834-2838. Impact factor : 6.578 [135] Fedirko V., Lukanova A., Bamia C., Trichopolou A., Trepo E., Nöthlings U., Schlesinger S., Aleksandrova K., Boffetta P., Tjonneland A., Johnsen N.F., Overvad K., Fagherazzi G., Racine A., Boutron-Ruault M.C., Grote V., Kaaks R., Boeing H., Naska A., Adarakis G., Valanou E., Palli D., Sieri S., Tumino R., Vineis P., Panico S., Bueno-de-Mesquita H.B., Siersema P.D., Peeters P.H., Weiderpass E., Skeie G., Engeset D., Quiros J.R., Zamora-Ros R., Sanchez M.J., Amiano P., Huerta J.M., Barricarte A., Johansen D., Lindkvist B., Sund M., Werner M., Crowe F., Khaw K.T., Ferrari P., Romieu I., Chuang S.C., Riboli E., and Jenab M. Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk of liver and biliary tract cancers in s. [2013] Annals of Oncology (24) 2 : 543-553. Impact factor : 6.578 [136] Fedirko V., Trichopolou A., Bamia C., Duarte-Salles T., Trepo E., Aleksandrova K., Nöthlings U., Lukanova A., Lagiou P., Boffetta P., Trichopoulos D., Katzke V.A., Overvad K., Tjonneland A., Hansen L., Boutron-Ruault M.C., Fagherazzi G., Bastide N., Panico S., Grioni S., Vineis P., Palli D., Tumino R., Bueno-de-Mesquita H.B., Peeters P.H., Skeie G., Engeset D., Parr C.L., Jakszyn P., Sanchez M.J., Barricarte A., Amiano P., Chirlaque M., Quiros J.R., Sund M., Werner M., Sonestedt E., Ericson U., Key T.J., Khaw K.T., Ferrari P., Romieu I., Riboli E., and Jenab M. Consumption of fish and meats and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition (EPIC). [2013] Annals of Oncology (24) 8 : 2166-2173. Impact factor : 6.578 [137] Garbay D., Maki R.G., Blay J.Y., Isambert N., Neumann S.P., Blay C., Zanardi E., Boudou-Rouquette P., Bozec L., Duffaud F., Bertucci F., and Italiano A. Advanced soft-tissue sarcoma in elderly patients: Patterns of care and survival. [2013] Annals of Oncology (24) 7 : 1924-1930. Impact factor : 6.578 [138] Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thürlimann B., Senn H.J., Albain K.S., André F., Bergh J., Bonnefoi H., Bretel-Morales D., Burstein H., Cardoso F., Castiglione-Gertsch M., Colleoni M., Costa A., Curigliano G., Davidson N.E., Leo A.D., Ejlertsen B., Forbes J.F., Gnant M., Goodwin P., Goss P.E., Harris J.R., Hayes D.F., Hudis C.A., Ingle J.N., Jassem J., Jiang Z., Karlsson P., Loibl S., Morrow M., Namer M., Osborne C.K., Partridge A.H., Penault-Llorca F., Perou C.M., Piccart-Gebhart M.J., Pritchard K.I., Rutgers E.J.T., Sedlmayer F., Semiglazov V., Shao Z.M., Smith I., Toi M., Tutt A., Untch M., Viale G., Watanabe T., Wilcken N., and Wood W.C. Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. [2013] Annals of Oncology (24) 9 : 2206-2223. Impact factor : 6.578 [139] Guarneri V., Dieci M.V., Barbieri E., Piacentini F., Omarini C., Ficarra G., Bettelli S., and Conte P.F. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. [2013] Annals of Oncology (24) 12 : 2990-2994. Impact factor : 6.578 [140] Horwich A., Hugosson J., de reijke T., Wiegel T., Fizazi K., Kataja V., Parker C., Bellmunt J., Berthold D., Bill-axelson A., Carlsson S., Daugaard G., De meerleer G., de reijke T., Dearnaley D., Fonteyne V., Gillessen S., Heinrich D., Kwiatkowski M., Nilsson S., Padhani A., Papandreou C., Roobol M., Sella A., Valdagni R., Van der kwast T., and Verhagen P. Prostate cancer: ESMO consensus conference guidelines 2012. [2013] Annals of Oncology (24) 5 : 1141-1162. Impact factor : 6.578 [141] Italiano A., Le Cesne A., Bellera C., Piperno-Neumann S., Duffaud F., Penel N., Cassier P., Domont J., Takebe N., Kind M., Coindre J.M., Blay J.Y., and Bui B. GDC-0449 in patients with advanced chondrosarcomas: A French sarcoma group/US and French national cancer institute single-arm phase ii collaborative study. [2013] Annals of Oncology (24) 11 : 2922-2926 . Impact factor : 6.578 [142] Italiano A., Mir O., Cioffi A., Palmerini E., Piperno-Neumann S., Perrin C., Chaigneau L., Penel N., Duffaud F., Kurtz J.E., Collard O., Bertucci F., Bompas E., Le Cesne A., Maki R.G., Ray I., and Blay J.Y. Advanced chondrosarcomas: Role of chemotherapy and survival. [2013] Annals of Oncology (24) 11 : 2916-2922. Impact factor : 6.578 [143] Izzedine H., Escudier B., Rouvier P., Gueutin V., Varga A., Bahleda R., and Soria J.C. Acute tubular necrosis associated with mTOR inhibitor therapy: A real entity biopsy-proven. [2013] Annals of Oncology (24) 9 : 2421-2425. Impact factor : 6.578 [144] Ketterer N., Coiffier B., Thieblemont C., Fermé C., Brière J., Casasnovas O., Bologna S., Christian B., Connerotte T., Récher C., Bordessoule D., Fruchart C., Delarue R., Bonnet C., Morschhauser F., Anglaret B., Soussain C., Fabiani B., Tilly H., and Haioun C. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1b). [2013] Annals of Oncology (24) 4 : 1032-1037. Impact factor : 6.578 [145] Le Péchoux C., Musat E., Baey C., Al Mokhles H., Terrier P., Domont J., Le Cesne A., Laplanche A., and Bonvalot S. Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? [2013] Annals of Oncology (24) 3 : 832-837. Impact factor : 6.578 [146] Ligthart S.T., Bidard F.C., Decraene C., Bachelot T., Delaloge S., Brain E., Campone M., Viens P., Pierga J.Y., and Terstappen L.W.M.M. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. [2013] Annals of Oncology (24) 5 : 1231-1238. Impact factor : 6.578 [147] Loriot Y., Bianchini D., Ileana E., Sandhu S., Patrikidou A., Pezaro C., Albiges L., Attard G., Fizazi K., De Bono J.S., and Massard C. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). [2013] Annals of Oncology (24) 7 : 1807-1812. Impact factor : 6.578 [148] Macaulay V.M., Middleton M.R., Protheroe A.S., Tolcher A., Dieras V., Sessa C., Bahleda R., Blay J.Y., LoRusso P., Mery-Mignard D., and Soria J.C. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. [2013] Annals of Oncology (24) 3 : 784-791. Impact factor : 6.578 [149] Massard C., Kramar A., Beyer J., Hartmann J.T., Lorch A., Pico J.L., Rosti G., Droz J.P., and Fizazi K. Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. [2013] Annals of Oncology (24) 2 : 322-328. Impact factor : 6.578 [150] Obon-Santacana M., Slimani N., Lujan-Barroso L., Travier N., Hallmans G., Freisling H., Ferrari P., Boutron-Ruault M.C., Racine A., Clavel F., Saieva C., Pala V., Tumino R., Mattiello A., Vineis P., Argüelles M., Ardanaz E., Amiano P., Navarro C., Sanchez M.J., Molina Montes E., Key T., Khaw K.T., Wareham N., Peeters P.H., Trichopoulou A., Bamia C., Trichopoulos D., Boeing H., Kaaks R., Katzke V., Ye W., Sund M., Ericson U., Wirfält E., Overvad K., Tjonneland A., Olsen A., Skeie G., Asli L.A., Weiderpass E., Riboli E., Bueno-de-Mesquita H.B., and Duell E.J. Dietary intake of acrylamide and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. [2013] Annals of Oncology (24) 10 : 2645-2651. Impact factor : 6.578 [151] Patrikidou A., Chabaud S., Ray-Coquard I., Bui B.N., Adenis A., Rios M., Bertucci F., Duffaud F., Chevreau C., Cupissol D., Domont J., Pérol D., Blay J.Y., and Le Cesne A. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: Results of the BFR14 prospective french sarcoma group randomised, phase III trial. [2013] Annals of Oncology (24) 4 : 1087-1093. Impact factor : 6.578 [152] Pautier P., Floquet A., Gladieff L., Bompas E., Ray-Coquard I., Piperno-Neumann S., Selle F., Guillemet C., Weber B., Largillier R., Bertucci F., Opinel P., Duffaud F., Reynaud-Bougnoux A., Delcambre C., Isambert N., Kerbrat P., Netter-Pinon G., Pinto N., Duvillard P., Haie-Meder C., Lhommé C., and Rey A. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. [2013] Annals of Oncology (24) 4 : 1099-1104. Impact factor : 6.578 [153] Pécuchet N., Bigot F., Gachet J., Massard C., Albiges L., Teghom C., Allory Y., Méjean A., Escudier B., and Oudard S. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. [2013] Annals of Oncology (24) 12 : 2963-2967. Impact factor : 6.578 [154] Penel N., Demetri G.D., Blay J.Y., Cousin S., Maki R.G., Chawla S.P., Judson I., Von Mehren M., Schöffski P., Verweij J., Casali P., Rodenhuis S., Schütte H.J., Cassar A., Gomez J., Nieto A., Zintl P., Pontes M.J., and Le Cesne A. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. [2013] Annals of Oncology (24) 2 : 537-542. Impact factor : 6.578 [155] Pierga J.Y., Bidard F.C., Cropet C., Tresca P., Dalenc F., Romieu G., Campone M., Aït-Oukhatar C.M., Rhun E.L., Gonçalves A., Leheurteur M., Dômont J., Gutierrez M., Curé H., Ferrero J.M., Labbe-Devilliers C., and Bachelot T. Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast Gustave Roussy 2013 / annexes rapport annuel 15 cancer: The LANDSCAPE trial. [2013] Annals of Oncology (24) 12 : 2999-3004. Impact factor : 6.578 [156] Rodrigues M.J., Peron J., Frénel J.S., Vano Y.A., Wassermann J., Debled M., Picaud F., Albiges L., Vincent-Salomon A., and Cottu P.H. Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: A multicenter retrospective series. [2013] Annals of Oncology (24) 4 : 916-924. Impact factor : 6.578 [157] Schlesinger S., Aleksandrova K., Pischon T., Jenab M., Fedirko V., Trepo E., Overvad K., Roswall N., Tjonneland A., Boutron-Ruault M.C., Fagherazzi G., Racine A., Kaaks R., Grote V.A., Boeing H., Trichopoulou A., Pantzalis M., Kritikou M., Mattiello A., Sieri S., Sacerdote C., Palli D., Tumino R., Peeters P.H., Bueno-de-Mesquita H.B., Weiderpass E., Quiros J.R., Zamora-Ros R., Sanchez M.J., Arriola L., Ardanaz E., Tormo M.J., Nilsson P., Lindkvist B., Sund M., Rolandsson O., Khaw K.T., Wareham N., Travis R.C., Riboli E., and Nothlings U. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. [2013] Annals of Oncology (24) 9 : 2449-2455. Impact factor : 6.578 [158] Sternberg C.N., Molina A., North S., Mainwaring P., Fizazi K., Hao Y., Rothman M., Gagnon D.D., Kheoh T., Haqq C.M., Cleeland C., De Bono J.S., and Scher H.I. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. [2013] Annals of Oncology (24) 4 : 1017-1025. Impact factor : 6.578 [159] Thariat J., Schouman T., Brouchet A., Sarini J., Miller R.C., Reychler H., Ray-Coquard I., Italiano A., Verite C., Sohawon S., Bompas E., Dassonville O., Salas S., Aldabbagh K., Maingon P., de la MotteRouge T., Kurtz J.E., Usseglio J., Kerbrat P., Raoul G., Lotz J.P., Bar-Sela G., Brugières L., Chaigneau L., Saada E., Odin G., Marcy P.Y., Thyss A., and Julieron M. Osteosarcomas of the mandible: Multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, rare cancer network, GETTEC/refcor and sfce. [2013] Annals of Oncology (24) 3 : 824-831. Impact factor : 6.578 [160] Postel-Vinay S., Schlumberger M., and Soria J.C. Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: Ordinary lapping or alarming waves foreshadowing disease progression? [2013] Annals of Oncology (24) 9 : 2201-2204. Impact factor : 6.578 [161] Sola B., Poirot M., De Medina P., Bustany S., Marsaud V., Silvente-Poirot S., and Renoir J.M. Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism. [2013] Oncotarget (4) 6 : 911-922. Impact factor : 6.627 [162] Thevenon J., Bourredjem A., Faivre L., Cardot-Bauters C., Calender A., Murat A., Giraud S., Niccoli P., Odou M.F., Borson-Chazot F., Barlier A., Lombard-Bohas C., Clauser E., Tabarin A., Parfait B., Chabre O., Castermans E., Beckers A., Ruszniewski P., Le bras M., Delemer B., Bouchard P., Guilhem I., Rohmer V., Goichot B., Caron P., Baudin E., Chanson P., Groussin L., Du boullay H., Weryha G., Lecomte P., Penfornis A., Bihan H., Archambeaud F., Kerlan V., Duron F., Kuhn J., Vergas B., Rodier M., Renard M., Sadoul J., Binquet C., and Goudet P. Higher risk of death among men1 patients with mutations in the jund interacting domain: A groupe d’étude des tumeurs endocrines (GTE) cohort study. 16 annexes rapport annuel / Gustave Roussy 2013 [2013] Human Molecular Genetics (22) 10 : 1940-1948. Impact factor : 6.677 [163] Romaguera D., Norat T., Wark P.A., Vergnaud A.C., Schulze M.B., van Woudenbergh G.J., Drogan D., Amiano P., Molina-Montes E., Sanchez M.J., Balkau B., Barricarte A., Beulens J.W.J., Clavel-Chapelon F., Crispim S.P., Fagherazzi G., Franks P.W., Grote V.A., Huybrechts I., Kaaks R., Key T.J., Khaw K.T., Nilsson P., Overvad K., Palli D., Panico S., Quiros J.R., Rolandsson O., Sacerdote C., Sieri S., Slimani N., Spijkerman A.M.W., Tjonneland A., Tormo M.J., Tumino R., van den Berg S.W., Wermeling P.R., Zamora-Ros R., Feskens E.J.M., Langenberg C., Sharp S.J., Forouhi N.G., Riboli E., and Wareham N.J. Consumption of sweet beverages and type 2 diabetes incidence in European adults: results from EPIC-InterAct. [2013] Diabetologia (56) 7 : 1520-1530. Impact factor : 6.880 [164] Fagherazzi G., Vilier A., Saes Sartorelli D., Lajous M., Balkau B., and Clavel-Chapelon F. Consumption of artificially and sugar-sweetened beverages and incident type 2 diabetes in the Etude Epidemiologique aupres des femmes de la Mutuelle Generale de l’Education Nationale-European Prospective Investigation into Cancer and Nutrition cohort. [2013] American journal of clinical nutrition (97) 3 : 517-523. Impact factor : 6.918 [165] Ferrari P., Rinaldi S., Jenab M., Lukanova A., Olsen A., Tjonneland A., Overvad K., Clavel-Chapelon F., Fagherazzi G., Touillaud M., Kaaks R., Von Rüsten A., Boeing H., Trichopoulou A., Lagiou P., Benetou V., Grioni S., Panico S., Masala G., Tumino R., Polidoro S., Bakker M.F., Van Gils C.H., Ros M.M., Bueno-de-Mesquita H.B., Krum-Hansen S., Engeset D., Skeie G., Pilar A., Sanchez M.J., Buckland G., Ardanaz E., Chirlaque D., Rodriguez L., Travis R., Key T., Khaw K.T., Wareham N.J., Sund M., Lenner P., Slimani N., Norat T., Aune D., Riboli E., and Romieu I. Dietary fiber intake and risk of hormonal receptor-defined breast cancer in the European prospective investigation into cancer and nutrition study. [2013] American journal of clinical nutrition (97) 2 : 344-353. Impact factor : 6.918 [166] Prado C.M., Sawyer M.B., Ghosh S., Lieffers J.R., Esfandiari N., Antoun S., and Baracos V.E. Central tenet of cancer cachexia therapy: Do patients with advanced cancer have exploitable anabolic potential? [2013] American journal of clinical nutrition (98) 4 : 1012-1019. Impact factor : 6.918 [167] Vergnaud A.C., Romaguera D., Peeters P.H., Van Gils C.H., Chan D.S.M., Romieu I., Freisling H., Ferrari P., Clavel-Chapelon F., Fagherazzi G., Dartois L., Li K., Tikk K., Bergmann M.M., Boeing H., Tjonneland A., Olsen A., Overvad K., Dahm C.C., Redondo M.L., Agudo A., Sanchez M.J., Amiano P., Chirlaque M.D., Ardanaz E., Khaw K.T., Wareham N.J., Crowe F., Trichopoulou A., Orfanos P., Trichopoulos D., Masala G., Sieri S., Tumino R., Vineis P., Panico S., Bueno-de-Mesquita H.B., Ros M.M., May A., Wirfalt E., Sonestedt E., Johansson I., Hallmans G., Lund E., Weiderpass E., Parr C.L., Riboli E., and Norat T. Adherence to the World Cancer Research Fund/American Institute for Cancer Research guidelines and risk of death in Europe: Results from the European Prospective Investigation into Nutrition and Cancer cohort study1-5. [2013] American journal of clinical nutrition (97) 5 : 1107-1120. Impact factor : 6.918 [168] Fagherazzi G. and Clavel-Chapelon F. Reply to HC Stevens and C La Vecchia : Artificially and sugar-sweetened beverages and incident type 2 diabetes. [2013] American journal of clinical nutrition (98) 1 : 250-251. Impact factor : 6.918 [169] Goéré D., Benhaim L., Bonnet S., Malka D., Faron M., Elias D., Lefèvre J.H., Deschamps F., Dromain C., Boige V., Dumont F., de Baere T., and Ducreux M. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. [2013] Annals of Surgery (257) 1 : 114-120. Impact factor : 7.188 [170] Goéré D., Malka D., Tzanis D., Gava V., Boige V., Eveno C., Maggiori L., Dumont F., Ducreux M., and Elias D. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? [2013] Annals of Surgery (257) 6 : 1065-1071. Impact factor : 7.188 [171] Maggiori L., Goéré D., Viana B., Tzanis D., Dumont F., Honoré C., Eveno C., and Elias D. Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent?: A case-control study. [2013] Annals of Surgery (258) 1 : 116-121. Impact factor : 7.188 [172] Grabarz A., Guirouilh-Barbat J., Barascu A., Pennarun G., Genet D., Rass E., Germann S.M., Bertrand P., Hickson I.D., and Lopez B.S. A Role for BLM in Double-Strand Break Repair Pathway Choice: Prevention of CtIP/Mre11-Mediated Alternative Nonhomologous End-Joining. [2013] Cell Reports (5) 1 : 21-28. Impact factor : 7.207 [173] Le Bihan Y.V., Matot B., Pietrement O., Giraud-Panis M.J., Gasparini S., Le Cam E., Gilson E., Sclavi B., Miron S., and Le Du M.H. Effect of Rap1 binding on DNA distortion and potassium permanganate hypersensitivity. [2013] Acta crystallographica. Section D, Biological crystallography (69) Pt 3 : 409-419. Impact factor : 7.232 [174] Li L., Ten Hagen T.L.M., Bolkestein M., Gasselhuber A., Yatvin J., Van Rhoon G.C., Eggermont A.M.M., Haemmerich D., and Koning G.A. Improved intratumoral nanoparticle extravasation and penetration by mild hyperthermia. [2013] Journal of Controlled Release (167) 2 : 130-137. Impact factor : 7.261 [175] Li L., Ten Hagen T.L.M., Hossann M., Süss R., Van Rhoon G.C., Eggermont A.M.M., Haemmerich D., and Koning G.A. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy. [2013] Journal of Controlled Release (168) 2 : 142150. Impact factor : 7.261 [176] Rohrmann S., Overvad K., Bueno-de-Mesquita H.B., Jakobsen M.U., Egeberg R., Tjonneland A., Nailler L., Boutron-Ruault M.C., Clavel-Chapelon F., Krogh V., Palli D., Panico S., Tumino R., Ricceri F., Bergmann M.M., Boeing H., Li K., Kaaks R., Khaw K.T., Wareham N.J., Crowe F.L., Key T.J., Naska A., Trichopoulou A., Trichopoulos D., Leenders M., Peeters P.H.M., Engeset D., Parr C.L., Skeie G., Jakszyn P., Sanchez M.J., Huerta J.M., Redondo M.L., Barricarte A., Amiano P., Drake I., Sonestedt E., Hallmans G., Johansson I., Fedirko V., Romieux I., Ferrari P., Norat T., Vergnaud A.C., Riboli E., and Linseisen A.J. Meat consumption and mortality - results from the European Prospective Investigation into Cancer and Nutrition. [2013] BMC Medicine (11) 1. Impact factor : 7.276 [177] Micha R., Michas G., Lajous M., and Mozaffarian D. Processing of meats and cardiovascular risk: Time to focus on preservatives. [2013] BMC Medicine (11) 1. Impact factor : 7.276 [178] Chung G.T.Y., Lung R.W.M., Hui A.B.Y., Yip K.Y.L., Woo J.K.S., Chow C., Tong C.Y.K., Lee S.D., Yuen J.W.F., Lun S.W.M., Tso K.K.Y., Wong N., Tsao S.W., Yip T.T.C., Busson P., Kim H., Seo J.S., O’Sullivan B., Liu F.F., To K.F., and Lo K.W. Identification of a recurrent transforming UBR5-ZNF423 fusion gene in EBV-associated nasopharyngeal carcinoma. [2013] Journal of Pathology (231) 2 : 158-167. Impact factor : 7.330 [179] Chung G.T.Y., Lou W.P.K., Chow C., To K.F., Choy K.W., Leung A.W.C., Tong C.Y.K., Yuen J.W.F., Ko C.W., Yip T.T.C., Busson P., and Lo K.W. Constitutive activation of distinct NF-kB signals in EBV-associated nasopharyngeal carcinoma. [2013] Journal of Pathology (231) 3 : 311-322 . Impact factor : 7.330 [180] Berois N., Gattolliat C.H., Barrios E., Capandeguy L., Douc-Rasy S., Valteau-Couanet D., Bénard J., and Osinaga E. GALNT9 gene expression is a prognostic marker in neuroblastoma patients. [2013] Clinical Chemistry (59) 1 : 225-233. Impact factor : 7.768 [181] Laforge M., Limou S., Harper F., Casartelli N., Rodrigues V., Silvestre R., Haloui H., Zagury J.F., Senik A., and Estaquier J. DRAM Triggers Lysosomal Membrane Permeabilization and Cell Death in CD4+ T Cells Infected with HIV. [2013] PLoS Pathogens (9) 5 : e1003328-e1003328. Impact factor : 8.057 [182] Laurenceau R., Péhau-Arnaudet G., Baconnais S., Gault J., Malosse C., Dujeancourt A., Campo N., Chamot-Rooke J., Le Cam E., Claverys J.P., and Fronzes R. A Type IV Pilus Mediates DNA Binding during Natural Transformation in Streptococcus pneumoniae. [2013] PLoS Pathogens (9) 6 . Impact factor : 8.057 [183] Le Bourhis L., Dusseaux M., Bohineust A., Bessoles S., Martin E., Premel V., Core M., Sleurs D., Serriari N.E., Treiner E., Hivroz C., Sansonetti P., Gougeon M.L., Soudais C., and Lantz O. MAIT Cells Detect and Efficiently Lyse Bacterially-Infected Epithelial Cells. [2013] PLoS Pathogens (9) 10. Impact factor : 8.057 [184] Couch F.J., Wang X., McGuffog L., Lee A., Olswold C., Kuchenbaecker K.B., Soucy P., Fredericksen Z., Barrowdale D., Dennis J., Gaudet M.M., Dicks E., Kosel M., Healey S., Sinilnikova O.M., Bacot F., Vincent D., Hogervorst F.B.L., Peock S., Stoppa-Lyonnet D., Jakubowska A., Radice P., Schmutzler R.K., Domchek S.M., Piedmonte M., Singer C.F., Friedman E., Thomassen M., Hansen T.V.O., Neuhausen S.L., Szabo C.I., Blanco I., Greene M.H., Karlan B.Y., Garber J., Phelan C.M., Weitzel J.N., Montagna M., Olah E., Andrulis I.L., Godwin A.K., Yannoukakos D., Goldgar D.E., Caldes T., Nevanlinna H., Osorio A., Terry M.B., Daly M.B., van Rensburg E.J., Hamann U., Ramus S.J., Ewart Toland A., Caligo M.A., Olopade O.I., Tung N., Claes K., Beattie M.S., Southey M.C., Imyanitov E.N., Tischkowitz M., Janavicius R., John E.M., Kwong A., Diez O., Balmano J., Barkardottir R.B., Arun B.K., Rennert G., Teo S.H., Ganz P.A., Campbell I., van der Hout A.H., van Deurzen C.H.M., Seynaeve C., Gomez-Garcia E.B., van Leeuwen F.E., Meijers-Heijboer H.E.J., Gille J.J.P., Ausems M.G.E.M., Blok M.J., Ligtenberg M.J.L., Rookus M.A., Devilee P., Verhoef S., van Os T.A.M., Wijnen J.T., Frost D., Ellis S., Fineberg E., Platte R., Evans D.G., Izatt L., Eeles R.A., Adlard J., Eccles D.M., Cook J., Brewer C., Douglas F., Hodgson S., Morrison P.J., Side L.E., Donaldson A., Houghton C., Rogers M.T., Dorkins H., Eason J., Gregory H., McCann E., Murray A., Calender A., Hardouin A., Berthet P., Delnatte C., Nogues C., Lasset C., Houdayer C., Leroux D., Rouleau Gustave Roussy 2013 / annexes rapport annuel 17 E., Prieur F., Damiola F., Sobol H., Coupier I., Venat-Bouvet L., Castera L., Gauthier-Villars M., Léoné M., Pujol P., Mazoyer S., Bignon Y.J., Zlowocka-Perlowska E., Gronwald J., Lubinski J., Durda K., Jaworska K., Huzarski T., Spurdle A.B., Viel A., Peissel B., Bonanni B., Melloni G., Ottini L., Papi L., Varesco L., Tibiletti M.G., Peterlongo P., Volorio S., Manoukian S., Pensotti V., Arnold N., Engel C., Deissler H., Gadzicki D., Gehrig A., Kast K., Rhiem K., Meindl A., Niederacher D., Ditsch N., Plendl H., Preisler-Adams S., Engert S., Sutter C., Varon-Mateeva R., Wappenschmidt B., Weber B.H.F., Arver B., Stenmark-Askmalm M., Loman N., Rosenquist R., Einbeigi Z., Nathanson K.L., Rebbeck T.R., Blank S.V., Cohn D.E., Rodriguez G.C., Small L., Friedlander M., BaeJump V.L., Fink-Retter A., Rappaport C., Gschwantler-Kaulich D., Pfeiler G., Tea M.K., Lindor N.M., Kaufman B., Shimon Paluch S., Laitman Y., Skytte A.B., Gerdes A.M., Pedersen I.S., Moeller S.T., Kruse T.A., Jensen U.B., Vijai J., Sarrel K., Robson M., Kauff N., Mulligan A.M., Glendon G., Ozcelik H., Ejlertsen B., Nielsen F.C., Jonson L., Andersen M.K., Ding Y.C., Steele L., Foretova L., Teulé A., Lazaro C., Brunet J., Pujana M.A., Mai P.L., Loud J.T., Walsh C., Lester J., Orsulic S., Narod S.A., Herzog J., Sand S.R., Tognazzo S., Agata S., Vaszko T., Weaver J., Stavropoulou A.V., Buys S.S., Romero A., de la Hoya M., Aittomäki K., Muranen T.A., Duran M., Chung W.K., Lasa A., Dorfling C.M., Miron A., Benitez J., Senter L., Huo D., Chan S.B., Sokolenko A.P., Chiquette J., Tihomirova L., Friebel T.M., Agnarsson B.A., Lu K.H., Lejbkowicz F., James P.A., Hall P., Dunning A.M., Tessier D., Cunningham J., Slager S.L., Wang C., Hart S., Stevens K., and Simard J. Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. [2013] PLoS Genetics (9) 3 : e1003212-e1003212. Impact factor : 8.167 [185] Esnault C., Cornelis G., Heidmann O., and Heidmann T. Differential Evolutionary Fate of an Ancestral Primate Endogenous Retrovirus Envelope Gene, the EnvV Syncytin, Captured for a Function in Placentation. [2013] PLoS Genetics (9) 3 : e1003400-e1003400. Impact factor : 8.167 [186] Esta A., Ma E., Dupaigne P., Maloisel L., Guerois R., Le Cam E., Veaute X., and Coïc E. Rad52 Sumoylation Prevents the Toxicity of Unproductive Rad51 Filaments Independently of the Anti-Recombinase Srs2. [2013] PLoS Genetics (9) 10 : e1003833-e1003833. Impact factor : 8.167 [187] Gaudet M.M., Kuchenbaecker K.B., Vijai J., Klein R.J., Kirchhoff T., McGuffog L., Barrowdale D., Dunning A.M., Lee A., Dennis J., Healey S., Dicks E., Soucy P., Sinilnikova O.M., Pankratz V.S., Wang X., Eldridge R.C., Tessier D.C., Vincent D., Bacot F., Hogervorst F.B.L., Peock S., Stoppa-Lyonnet D., Coulet F., Colas C., Soubrier F., Peterlongo P., Schmutzler R.K., Nathanson K.L., Piedmonte M., Singer C.F., Thomassen M., Sokolowska J., Bronner M., Hansen T.V.O., Neuhausen S.L., Blanco I., Greene M.H., Garber J., Weitzel J.N., Andrulis I.L., Goldgar D.E., D’Andrea E., Caldes T., Nevanlinna H., Osorio A., van Rensburg E.J., Arason A., Rennert G., van den Ouweland A.M.W., van der Hout A.H., Kets C.M., Aalfs C.M., Wijnen J.T., Ausems M.G.E.M., Frost D., Ellis S., Fineberg E., Platte R., Evans D.G., Jacobs C., Adlard J., Tischkowitz M., Porteous M.E., Damiola F., Golmard L., Barjhoux L., Longy M., Belotti M., Ferrer S.F., Mazoyer S., Spurdle A.B., Manoukian S., Barile M., Genuardi M., Arnold N., Meindl A., Sutter C., Wappenschmidt B., Domchek S.M., Pfeiler G., Friedman E., 18 annexes rapport annuel / Gustave Roussy 2013 Jensen U.B., Robson M., Shah S., Lazaro C., Mai P.L., Benitez J., Southey M.C., Schmidt M.K., Fasching P.A., Peto J., Humphreys M.K., Wang Q., Michailidou K., Sawyer E.J., Burwinkel B., Guénel P., Bojesen S.E., Milne R.L., Brenner H., Lochmann M., Brauch H., Ko Y.D., Baisch C., Fischer H.P., Bruening T., Pesch B., Rabstein S., Spickenheuer A., Aittomäki K., Dörk T., Margolin S., Mannermaa A., Lambrechts D., Chang-Claude J., Radice P., Giles G.G., Haiman C.A., Winqvist R., Devillee P., Garcia-Closas M., Schoof N., Hooning M.J., Cox A., Pharoah P.D.P., Jakubowska A., Orr N., Gonzalez-Neira A., Pita G., Alonso M.R., Hall P., Couch F.J., Simard J., Altshuler D., Easton D.F., Chenevix-Trench G., Antoniou A.C., Offit K., Rookus M.A., van Leeuwen F.E., Verhoef S., de Lange J.L., Collée J.M., Seynaeve C., van Deurzen C.H.M., van Asperen C.J., Tollenaar R.A., Devilee P., van Cronenburg T.C.T.E., Mensenkamp A.R., van der Luijt R.B., van Os T.A.M., Gille J.J.P., Waisfisz Q., Meijers-Heijboer H.E.J., Gomez-Garcia E.B., Blok M.J., Oosterwijk J.C., Mourits M.J., de Bock G.H., Vasen H.F., Miedzybrodzka Z., Gregory H., Morrison P., Jeffers L., Cole T., Ong K.R., Hoffman J., Donaldson A., James M., Paterson J., Taylor A., Murray A., Rogers M.T., McCann E., Kennedy M.J., Barton D., Porteous M., Drummond S., Brewer C., Kivuva E., Searle A., Goodman S., Hill K., Davidson R., Murday V., Bradshaw N., Snadden L., Longmuir M., Watt C., Gibson S., Haque E., Tobias E., Duncan A., Izatt L., Langman C., Brady A., Dorkins H., Melville A., Randhawa K., Barwell J., Serra-Feliu G., Ellis I., Houghton C., Lalloo F., Taylor J., Side L., Male A., Berlin C., Eason J., Collier R., Douglas F., Claber O., Jobson I., Walker L., McLeod D., Halliday D., Durell S., Stayner B., Eeles R.A., Shanley S., Rahman N., Houlston R., Bancroft E., Page E., Ardern-Jones A., Kohut K., Wiggins J., Castro E., Killick E., Martin S., Rea G., Kulkarni A., Cook J., Quarrell O., Bardsley C., Hodgson S., Goff S., Brice G., Winchester L., Eddy C., Tripathi V., Attard V., Lehmann A., Eccles D., Lucassen A., Crawford G., McBride D., Smalley S., Sinilnikova O., Verny-Pierre C., Giraud S., Léone M., and Gauthier-Villars M. Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. [2013] PLoS Genetics (9) 3 : e1003173-e1003173. Impact factor : 8.167 [188] Ferté C., Trister A.D., Huang E., Bot B.M., Guinney J., Commo F., Sieberts S., André F., Besse B., Soria J.C., and Friend S.H. Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. [2013] Clinical Cancer Research (19) 16 : 4315-4325. Impact factor : 8.193 [189] Andre F., Dieci M.V., Dubsky P., Sotiriou C., Curigliano G., Denkert C., and Loi S. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. [2013] Clinical Cancer Research (19) 1 : 28-33. Impact factor : 8.193 [190] André F., Bachelot T., Campone M., Dalenc F., Perez-Garcia J.M., Hurvitz S.A., Turner N., Rugo H., Smith J.W., Deudon S., Shi M., Zhang Y., Kay A., Porta D.G., Yovine A., and Baselga J. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. [2013] Clinical Cancer Research (19) 13 : 36933702. Impact factor : 8.193 [191] Angevin E., Lopez-Martin J.A., Lin C.C., Gschwend J.E., Harzstark A., Castellano D., Soria J.C., Sen P., Chang J., Shi M., Kay A., and Escudier B. Phase i study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. [2013] Clinical Cancer Research (19) 5 : 12571268. Impact factor : 8.193 [192] Gini B., Zanca C., Guo D., Matsutani T., Masui K., Ikegami S., Yang H., Nathanson D., Villa G.R., Shackelford D., Zhu S., Tanaka K., Babic I., Akhavan D., Lin K., Assuncao A., Gu Y., Bonetti B., Mortensen D.S., Xu S., Raymon H.K., Cavenee W.K., Furnari F.B., James C.D., Kroemer G., Heath J.R., Hege K., Chopra R., Cloughesy T.F., and Mischel P.S. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. [2013] Clinical Cancer Research (19) 20 : 5722-5732. Impact factor : 8.193 [193] Italiano A., Lagarde P., Brulard C., Terrier P., Laë M., Marques B., Ranchere-Vince D., Michels J.J., Trassard M., Cioffi A., Piperno-Neumann S., Chevreau C., Blay J.Y., Delcambre C., Isambert N., Penel N., Bay J.O., Bonvalot S., Le Cesne A., Coindre J.M., and Chibon F. Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics. [2013] Clinical Cancer Research (19) 5 : 1190-1196 . Impact factor : 8.193 [194] Malouf G.G., Monzon F.A., Couturier J., Molinié V., Escudier B., Camparo P., Su X., Yao H., Tamboli P., Lopez-Terrada D., Picken M., Garcia M., Multani A.S., Pathak S., Wood C.G., and Tannir N.M. Genomic heterogeneity of translocation renal cell carcinoma. [2013] Clinical Cancer Research (19) 17 : 4673-4684. Impact factor : 8.193 [195] Ott P.A., Hodi F.S., and Robert C. CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. [2013] Clinical Cancer Research (19) 19 : 5300-5309. Impact factor : 8.193 [196] Robert C., Schadendorf D., Messina M., Hodi F.S., and O’Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. [2013] Clinical Cancer Research (19) 8 : 2232-2239. Impact factor : 8.193 [197] Ryan C.J., Rosenthal M., Ng S., Alumkal J., Picus J., Gravis G., Fizazi K., Forget F., Machiels J.P., Srinivas S., Zhu M., Tang R., Oliner K.S., Jiang Y., Loh E., Dubey S., and Gerritsen W.R. Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. [2013] Clinical Cancer Research (19) 1 : 215-224. Impact factor : 8.193 [198] Sessa C., LoRusso P., Tolcher A., Farace F., Lassau N., Delmonte A., Braghetti A., Bahleda R., Cohen P., Hospitel M., VeyratFollet C., and Soria J.C. Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. [2013] Clinical Cancer Research (19) 17 : 4832-4842. Impact factor : 8.193 [199] Vassal G., Geoerger B., and Morland B. Is the European Pediatric Medicine Regulation working for children and adolescents with cancer? [2013] Clinical Cancer Research (19) 6 : 1315-1325. Impact factor : 8.193 [200] El Behi M., Krumeich S., Lodillinsky C., Kamoun A., Tibaldi L., Sugano G., De Reynies A., Chapeaublanc E., Laplanche A., Lebret T., Allory Y., Radvanyi F., Lantz O., Eijan A.M., Bernard-Pierrot I., and Thery C. An essential role for decorin in bladder cancer invasiveness. [2013] EMBO Molecular Medicine (5) 12 : 1835-1851. Impact factor : 8.245 [201] Gallo V., Wark P.A., Jenab M., Pearce N., Brayne C., Vermeulen R., Andersen P.M., Hallmans G., Kyrozis A., Vanacore N., Vahdaninia M., Grote V., Kaaks R., Mattiello A., Bas Bueno-De-mesquita H., Peeters P.H., Travis R.C., Petersson J., Hansson O., Arriola L., Martin J.M.J., Tjonneland A., Halkjaer J., Agnoli C., Sacerdote C., Bonet C., Trichopoulou A., Gavrila D., Overvad K., Weiderpass E., Palli D., Quiros J.R., Tumino R., Khaw K.T., Wareham N., Barricante-Gurrea A., Fedirko V., Ferrari P., Clavel-Chapelon F., Ruault M.C.B., Boeing H., Vigl M., Middleton L., Riboli E., and Vineis P. Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: The EPIC cohort. [2013] Neurology (80) 9 : 829-838. Impact factor : 8.303 [202] Mathon B., Blauwblomme T., Bolle S., Dufour C., Nagarra O., Brunelle F., and Puget S. De novo arteriovenous malformation after brain radiotherapy for medulloblastoma in a child. [2013] Neurology (81) 4 : 398-399. Impact factor : 8.303 [203] Büttner S., Faes L., Reichelt W.N., Broeskamp F., Habernig L., Benke S., Kourtis N., Ruli D., Carmona-Gutierrez D., Eisenberg T., D’hooge P., Ghillebert R., Franssens V., Harger A., Pieber T.R., Freudenberger P., Kroemer G., Sigrist S.J., Winderickx J., Callewaert G., Tavernarakis N., and Madeo F. The Ca 2+/Mn 2+ ion-pump PMR1 links elevation of cytosolic Ca 2+ levels to a-synuclein toxicity in Parkinson’s disease models. [2013] Cell Death and Differentiation. Impact factor : 8.385 [204] Jemaa M., Galluzzi L., Kepp O., Senovilla L., Brands M., Boemer U., Koppitz M., Lienau P., Prechtl S., Schulze V., Siemeister G., Wengner A.M., Mumberg D., Ziegelbauer K., Abrieu A., Castedo M., Vitale I., and Kroemer G. Characterization of novel MPS1 inhibitors with preclinical anticancer activity. [2013] Cell Death and Differentiation (20) 11 : 1532-1545. Impact factor : 8.385 [205] Ridinger-Saison M., Evanno E., Gallais I., Rimmelé P., Selimoglu-Buet D., Sapharikas E., Moreau-Gachelin F., and Guillouf C. Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia. [2013] Cell Death and Differentiation (20) 9 : 1268-1278. Impact factor : 8.385 [206] Villella V.R., Esposito S., Bruscia E.M., Vicinanza M., Cenci S., Guido S., Pettoello-Mantovani M., Carnuccio R., De Matteis M.A., Luini A., Maiuri M.C., Raia V., Kroemer G., and Maiuri L. Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator. [2013] Cell Death and Differentiation (20) 8 : 1101-1115. Impact factor : 8.385 [207] Fimia G.M., Kroemer G., and Piacentini M. Molecular mechanisms of selective autophagy. [2013] Cell Death and Differentiation (20) 1 : 1-2. Impact factor : 8.385 [208] Galluzzi L., Vacchelli E., Michels J., Garcia P., Kepp O., Senovilla L., Vitale I., and Kroemer G. Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. [2013] Oncogene (32) 42 : 4995-5004. Impact factor : 8.559 [209] Vainchenker W. and Constantinescu S.N. JAK/STAT signaling in hematological malignancies. [2013] Oncogene (32) 21 : 26012613. Impact factor : 8.559 [210] Lainey E., Wolfromm A., Marie N., Enot D., Scoazec M., Bouteloup C., Leroy C., Micol J.B., De Botton S., Galluzzi L., Fenaux P., and Kroemer G. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. [2013] Oncogene. Impact factor : 8.559 Gustave Roussy 2013 / annexes rapport annuel 19 [211] Postel-Vinay S., Bajrami I., Friboulet L., Elliott R., Fontebasso Y., Dorvault N., Olaussen K.A., André F., Soria J.C., Lord C.J., and Ashworth A. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. [2013] Oncogene (32) 47 : 5377-5387. Impact factor : 8.559 [212] Yao Z., Jones A.W.E., Fassone E., Sweeney M.G., Lebiedzinska M., Suski J.M., Wieckowski M.R., Tajeddine N., Hargreaves I.P., Yasukawa T., Tufo G., Brenner C., Kroemer G., Rahman S., and Szabadkai G. PGC-1ß mediates adaptive chemoresistance associated with mitochondrial DNA mutations. [2013] Oncogene. Impact factor : 8.559 [213] Brand J.S., van der Schouw Y.T., Onland-Moret N.C., Sharp S.J., Ong K.K., Khaw K.T., Ardanaz E., Amiano P., Boeing H., Chirlaque M.D., Clavel-Chapelon F., Crowe F.L., de Lauzon-Guillain B., Duell E.J., Fagherazzi G., Franks P.W., Grioni S., Groop L.C., Kaaks R., Key T.J., Nilsson P.M., Overvad K., Palli D., Panico S., Quiros J.R., Rolandsson O., Sacerdote C., Sánchez M.a.J., Slimani N., Teucher B., Tjonneland A., Tumino R., van d.A., Feskens E.J.M., Langenberg C., Forouhi N.G., Riboli E., and Wareham N.J. Age at menopause, reproductive life span, and type 2 diabetes risk: results from the EPIC-InterAct study. [2013] Diabetes care (36) 4 : 1012-1019. Impact factor : 8.570 [214] Lajous M., Tondeur L., Fagherazzi G., De Lauzon-Guillain B., Boutron-Ruaualt M.C., and Clavel-Chapelon F. Childhood and adult secondhand smoke and type 2 diabetes in women. [2013] Diabetes care (36) 9 : 2720-2725. Impact factor : 8.570 [215] Zamora-Ros R., Forouhi N.G., Sharp S.J., Gonzalez C.A., Buijsse B., Guevara M., van der Schouw Y.T., Amiano P., Boeing H., Bredsdorff L., Clavel-Chapelon F., Fagherazzi G., Feskens E.J., Franks P.W., Grioni S., Katzke V., Key T.J., Khaw K.T., Kühn T., Masala G., Mattiello A., Molina-Montes E., Nilsson P.M., Overvad K., Perquier F., Quiros J.R., Romieu I., Sacerdote C., Scalbert A., Schulze M., Slimani N., Spijkerman A.M.W., Tjonneland A., Tormo M.J., Tumino R., van d.A., Langenberg C., Riboli E., and Wareham N.J. The association between dietary flavonoid and lignan intakes and incident type 2 diabetes in European populations: the EPIC-InterAct study. [2013] Diabetes care (36) 12 : 3961-3970. Impact factor : 8.570 [216] Daraï E., Fauvet R.L., Uzan C., Gouy S., Duvillard P., and Morice P. Fertility and borderline ovarian tumor: A systematic review of conservative management, risk of recurrence and alternative options. [2013] Human Reproduction Update (19) 2 : 138-139. Impact factor : 8.657 [217] Bacquin A., Pouvelle C., Siaud N., Perderiset M., Salomé-Desnoulez S., Tellier-Lebegue C., Lopez B., Charbonnier J.B., and Kannouche P.L. The helicase FBH1 is tightly regulated by PCNA via CRL4(Cdt2)-mediated proteolysis in human cells. [2013] Nucleic acids research (41) 13 : 6501-6513. Impact factor : 8.808 [218] Huret J.L., Ahmad M., Arsaban M., Bernheim A., Cigna J., Desangles F., Guignard J.C., Jacquemot-Perbal M.C., Labarussias M., Leberre V., Malo A., Morel-Pair C., Mossafa H., Potier J.C., Texier G., Viguié F., Wan-Senon S.Y.C., Zasadzinski A., and Dessen P. Atlas of genetics and cytogenetics in oncology and haematology in 2013. [2013] Nucleic acids research (41) D1 : D920-D924. Impact factor : 8.808 [219] Talhaoui I., Couvé S., Ishchenko A.A., Kunz C., Schär P., and Sapa- 20 annexes rapport annuel / Gustave Roussy 2013 rbaev M. 7,8-dihydro-8-oxoadenine, a highly mutagenic adduct, is repaired by Escherichia coli and human mismatch-specific uracil/thymine-DNA glycosylases. [2013] Nucleic acids research (41) 2 : 912-923. Impact factor : 8.808 [220] Chargari C., Clemenson C., Martins I., Perfettini J.L., and Deutsch E. Understanding the functions of tumor stroma in resistance to ionizing radiation: Emerging targets for pharmacological modulation. [2013] Drug Resistance Updates (16) 1-2 : 10-21. Impact factor : 8.816 [221] Pietrocola F., Izzo V., Niso-Santano M., Vacchelli E., Galluzzi L., Maiuri M.C., and Kroemer G. Regulation of autophagy by stress-responsive transcription factors. [2013] Seminars in Cancer Biology (23) 5 : 310-322. Impact factor : 9.143 [222] Richard S., Gardie B., Couvé S., and Gad S. Von Hippel-Lindau: How a rare disease illuminates cancer biology. [2013] Seminars in Cancer Biology. Impact factor : 9.143 [223] Dossus L., Kvaskoff M., Bijon A., Engel P., Verdebout J., Fervers B., Boutron-Ruault M.C., Clavel-Chapelon F., and Mesrine S. Latitude and ultraviolet radiation dose in the birthplace in relation to menarcheal age in a large cohort of french women. [2013] International Journal of Epidemiology (42) 2 : 590-600. Impact factor : 9.197 [224] Akalay I., Janji B., Hasmim M., Noman M.Z., André F., De Cremoux P., Bertheau P., Badoual C., Vielh P., Larsen A.K., Sabbah M., Tan T.Z., Keira J.H., Hung N.T.Y., Thiery J.P., Mami-Chouaib F., and Chouaib S. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from t-cell-mediated lysis. [2013] Cancer Research (73) 8 : 24182427. Impact factor : 9.284 [225] Casetti L., Martin-Lannerée S., Najjar I., Plo I., Augé S., Roy L., Chomel J.C., Lauret E., Turhan A.G., and Dusanter-Fourt I. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. [2013] Cancer Research (73) 7 : 2052-2058. Impact factor : 9.284 [226] Chantöme A., Potier-Cartereau M., Clarysse L., Fromont G., Marionneau-Lambot S., Guéguinou M., Pagés J.C., Collin C., Oullier T., Girault A., Arbion F., Haelters J.P., Jaffré P.A., Pinault M., Besson P., Joulin V., Bougnoux P., and Vandier C. Pivotal role of the lipid raft SK3-orai1 complex in human cancer cell migration and bone metastases. [2013] Cancer Research (73) 15 : 4852-4861. Impact factor : 9.284 [227] Franciszkiewicz K., Le Floc’h A., Boutet M., Vergnon I., Schmitt A., and Mami-Chouaib F. CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions. [2013] Cancer Research (73) 2 : 617-628. Impact factor : 9.284 [228] Goéré D., Flament C., Rusakiewicz S., Poirier-Colame V., Kepp O., Martins I., Pesquet J., Eggermont A., Elias D., Chaput N., and Zitvogel L. Potent immunomodulatory effects of the trifunctional antibody catumaxomab. [2013] Cancer Research (73) 15 : 46634673. Impact factor : 9.284 [229] Laderach D.J., Gentilini L.D., Giribaldi L., Delgado V.C., Nugnes L., Croci D.O., Al Nakouzi N., Sacca P., Casas G., Mazza O., Shipp M.A., Vazquez E., Chauchereau A., Kutok J.L., Rodig S.J., Elola M.T., Compagno D., and Rabinovich G.A. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. [2013] Cancer Research (73) 1 : 86-96. Impact factor : 9.284 [230] Michels J., Vitale I., Galluzzi L., Adam J., Olaussen K.A., Kepp O., Senovilla L., Talhaoui I., Guegan J., Enot D.P., Talbot M., Robin A., Girard P., Orear C., Lissa D., Sukkurwala A.Q., Garcia P., Behnam-Motlagh P., Kohno K., Wu G.S., Brenner C., Dessen P., Saparbaev M., Soria J.C., Castedo M., and Kroemer G. Cisplatin resistance associated with PARP hyperactivation. [2013] Cancer Research (73) 7 : 2271-2280. Impact factor : 9.284 [231] Molina A., Velot L., Ghouinem L., Abdelkarim M., Bouchet B.P., Luissint A.C., Bouhlel I., Morel M., Sapharikas E., Di Tommaso A., Honoré S., Braguer D., Gruel N., Vincent-Salomon A., Delattre O., Sigal-Zafrani B., André F., Terris B., Akhmanova A., Di Benedetto M., Nahmias C., and Rodrigues-Ferreira S. ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics. [2013] Cancer Research (73) 9 : 29052915. Impact factor : 9.284 232. Quidville V., Alsafadi S., Goubar A., Commo F., Scott V., Pioche-Durieu C., Girault I., Baconnais S., Le Cam E., Lazar V., Delaloge S., Saghatchian M., Pautier P., Morice P., Dessen P., Vagner S., and Andre F. Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. [2013] Cancer Research (73) 7 : 2247-2258. Impact factor : 9.284 [233] Rusakiewicz S., Semeraro M., Sarabi M., Desbois M., Locher C., Mendez R., Vimond N., Concha A., Garrido F., Isambert N., Chaigneau L., Le Brun-Ly V., Dubreuil P., Cremer I., Caignard A., Poirier-Colame V., Chaba K., Flament C., Halama N., Jag̈er D., Eggermont A., Bonvalot S., Commo F., Terrier P., Opolon P., Emile J.F., Coindre J.M., Kroemer G., Chaput N., Le Cesne A., Blay J.Y., and Zitvogel L. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. [2013] Cancer Research (73) 12 : 3499-3510. Impact factor : 9.284 [234] Marty C., Lacout C., Droin N., Le Couédic J.P., Ribrag V., Solary E., Vainchenker W., Villeval J.L., and Plo I. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. [2013] Leukemia (27) 11 : 2187-2195. Impact factor : 9.379 [235] Itzykson R. and Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. [2013] Leukemia (27) 7 : 1441-1450. Impact factor : 9.379 [236] Vainchenker W. and Favale F. Myelofibrosis, JAK2 inhibitors and erythropoiesis. [2013] Leukemia (27) 6 : 1219-1223. Impact factor : 9.379 [237] Damm F., Itzykson R., Kosmider O., Droin N., Renneville A., Chesnais V., Gelsi-Boyer V., De Botton S., Vey N., Preudhomme C., Clavert A., Delabesse E., Park S., Birnbaum D., Fontenay M., Bernard O.A., and Solary E. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. [2013] Leukemia (27) 6 : 1401-1403. Impact factor : 9.379 [238] Kosmider O., Itzykson R., Chesnais V., Lasho T., Laborde R., Knudson R., Gauthier A., Merlevede J., Ades L., Morabito M., Fontenay M., Tefferi A., Droin N., and Solary E. Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. [2013] Leukemia (27) 9 : 1946-1949. Impact factor : 9.379 [239] Schmidt M., Sonneville R., Schnell D., Bigé N., Hamidfar R., Mongardon N., Castelain V., Razazi K., Marty A., Vincent F., Dres M., Gaudry S., Luyt C.E., Das V., Micol J.B., Demoule A., and Mayaux J. Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: A multicenter study. [2013] Clinical Infectious Diseases (57) 11 : 1535-1541. Impact factor : 9.416 [240] Bergoglio V., Boyer A.S., Walsh E., Naim V., Legube G., Lee M.Y.W.T., Rey L., Rosselli F., Cazaux C., Eckert K.A., and Hoffmann J.S. DNA synthesis by pol n promotes fragile site stability by preventing under-replicated DNA in mitosis. [2013] Journal of Cell Biology (201) 3 : 395-408. Impact factor : 9.688 [241] Chen Y., Aardema J., Kale S., Whichard Z.L., Awomolo A., Blanchard E., Chang B., Myers D.R., Ju L., Tran R., Reece D., Christensen H., Boukour S., Debili N., Strom T.S., Rawlings D., Vazquez F.X., Voth G.A., Zhu C., Kahr W.H.A., Lam W.A., and Corey S.J. Loss of the F-BAR protein CIP4 reduces platelet production by impairing membrane-cytoskeleton remodeling. [2013] Blood (122) 10 : 1695-1706. Impact factor : 9.775 [242] Damm F., Chesnais V., Nagata Y., Yoshida K., Scourzic L., Okuno Y., Itzykson R., Sanada M., Shiraishi Y., Gelsi-Boyer V., Renneville A., Miyano S., Mori H., Shih L.Y., Park S., Dreyfus F., Guerci-Bresler A., Solary E., Rose C., Cheze S., Prébet T., Vey N., Legentil M., Duffourd Y., Botton S.D., Preudhomme C., Birnbaum D., Bernard O.A., Ogawa S., Fontenay M., and Kosmider O. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. [2013] Blood (122) 18 : 3169-3177. Impact factor : 9.775 [243] Delarue R., Haioun C., Ribrag V., Brice P., Delmer A., Tilly H., Salles G., Van Hoof A., Casasnovas O., Brousse N., Lefrere F., and Hermine O. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. [2013] Blood (121) 1 : 48-53. Impact factor : 9.775 [244] Gerrard M., Waxman I.M., Sposto R., Aupérin A., Perkins S.L., Goldman S., Harrison L., Pinkerton R., McCarthy K., Raphael M., Patte C., and Cairo M.S. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. [2013] Blood (121) 2 : 278-285. Impact factor : 9.775 [245] Hasan S., Lacout C., Marty C., Cuingnet M., Solary E., Vainchenker W., and Villeval J.L. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNa. [2013] Blood (122) 8 : 1464-1477. Impact factor : 9.775 [246] Itzykson R., Kosmider O., Renneville A., Morabito M., Preudhomme C., Berthon C., Ades L., Fenaux P., Platzbecker U., Gagey O., Rameau P., Meurice G., Orear C., Delhommeau F., Bernard O.A., Fontenay M., Vainchenker W., Droin N., and Solary E. Clonal architecture of chronic myelomonocytic leukemias. [2013] Blood (121) 12 : 2186-2198. Impact factor : 9.775 [247] Malinge S., Thiollier C., Chlon T.M., Doré L.C., Diebold L., Bluteau O., Mabialah V., Vainchenker W., Dessen P., Winandy S., Mercher T., and Crispino J.D. Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. [2013] Blood (121) 13 : 2440-2451. Impact factor : 9.775 [248] Pleines I., Dütting S., Cherpokova D., Eckly A., Meyer I., Morowski Gustave Roussy 2013 / annexes rapport annuel 21 M., Krohne G., Schulze H., Gachet C., Debili N., Brakebusch C., and Nieswandt B. Defective tubulin organization and proplatelet formation in murine megakaryocytes lacking Rac1 and Cdc42. [2013] Blood (122) 18 : 3178-3187. Impact factor : 9.775 [249] Roux C., Nicolini F.E., Rea D., Niault M., Mollica L., Berger F., Chassagne-Clément C., Tigaud I., Tulliez M., Giraudier S., Turhan A., Rousselot P., and Legros L. Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase. [2013] Blood (122) 17 : 30823084. Impact factor : 9.775 [250] Allouch A., David A., Amie S.M., Lahouassa H., Chartier L., Margottin-Goguet F., Barré-Sinoussi F., Kim B., Saez-Cirion A., and Pancino G. P21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. [2013] Proceedings of the National Academy of Sciences of the United States of America (110) 42 : E3997-E4006. Impact factor : 9.809 [251] Baginska J., Viry E., Berchem G., Poli A., Noman M.Z., Van Moer K., Medves S., Zimmer J., Oudin A., Niclou S.P., Bleackley R.C., Goping I.S., Chouaib S., and Janji B. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. [2013] Proceedings of the National Academy of Sciences of the United States of America (110) 43 : 17450-17455. Impact factor : 9.809 [252] Cornelis G., Heidmann O., Degrelle S.A., Vernochet C., Lavialle C., Letzelter C., Bernard-Stoecklin S., Hassanin A., Mulot B., Guillomot M., Hue I., Heidmann T., and Dupressoir A. Captured retroviral envelope syncytin gene associated with the unique placental structure of higher ruminants. [2013] Proceedings of the National Academy of Sciences of the United States of America (110) 9 : E828-E837. Impact factor : 9.809 [253] Mazouzi A., Vigouroux A., Aikeshev B., Brooks P.J., Saparbaev M.K., Morera S., and Ishchenko A.A. Insight into mechanisms of 3’-5’ exonuclease activity and removal of bulky 8,5’-cyclopurine adducts by apurinic/apyrimidinic endonucleases. [2013] Proceedings of the National Academy of Sciences of the United States of America (110) 33 : E3071-E3080. Impact factor : 9.809 [254] Prorok P., Alili D., Saint-Pierre C., Gasparutto D., Zharkov D.O., Ishchenko A.A., Tudek B., and Saparbaev M.K. Uracil in duplex DNA is a substrate for the nucleotide incision repair pathway in human cells. [2013] Proceedings of the National Academy of Sciences of the United States of America (110) 39 : E3695-E3703. Impact factor : 9.809 22 annexes rapport annuel / Gustave Roussy 2013 Retouvez la liste des publications à Impact Factor entre 10 et 20 et supérieur à 20 dans l’espace rapports annuels du site internet de Gustave Roussy